MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 A Phase  II Clinical  Trial  of Lenalidomide  Intensification  in Patients  with 
Serologic/  As ymptomatic  Progression  of Multiple  Myeloma  While  on 
Lenalidomide  Maintenance  
 
PROTOCOL  FACE  PAGE FOR  
MSKCC THERAPEUTIC/DIAGNOSTIC PROTOCOL 
 
Principal  Hani  Hassoun,  MD Medicine:  Lymphoma/Myeloma  
Co-Principal  
Investigator(s)/Department : Sergio  Giralt,  MD Medicine:  BMT  
Investigator(s)/Department: David  Chung,  MD 
Heather  Landau,  MD 
Nikoletta  Lendvai,  MD, PhD 
Alex  Lesokhin,  MD 
Elyn Riedel,  MA 
Ephraim  Casper,  MD 
Audrey  Hamilton,  MD 
Mila  Gorsky,  MD 
Han Xiao,  MD 
John  Fiore,  MD 
Stuart  Lichtman,  MD 
Steven  Sugarman,  MD 
Arlyn  Apollo,  MD 
Pamela  Drullinsky,   MD 
Zoe Goldberg,  MD 
Kenneth  Ng, MD 
Tiffany  Troso -Sandoval,  MD 
Michelle  Boyar,  MD 
Philip  Caron,  MD,  PhD 
Nancy  Mills,  MD 
Stephanie  Smith -Marrone,  MD 
Carolyn  Wasserheit -Lieblich,  MD 
Anna  Dee,  MS, NP-C 
Ewa Chauvin,  MSN,  ANP -C Medicine:  BMT  
Medicine:  BMT  
Medicine:  Lymphoma/Myeloma  
Medicine:  Lymphoma/Myeloma  
Epidemiology  and Biostatistics  
Medicine:  All Network  Sites  
Medicine:  Basking  Ridge  
Medicine:  Basking  Ridge  
Medicine:  Basking  Ridge  
Medicine:  Commack  
Medicine:  Commack  
Medicine:  Commack  
Medicine:  Rockville  Centre  
Medicine:  Rockville  Centre  
Medicine:  Rockville  Centre  
Medicine:  Rockville  Centre  
Medicine:  Rockville  Centre  
Medicine:  Sleepy  Hollow  
Medicine:  Sleepy  Hollow  
Medicine:  Sleepy  Hollow  
Medicine:  Sleepy  Hollow  
Medicine:  Sleepy  Hollow  
Medicine:  BMT  
Medicine:  Myeloma  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 Consenting  
Professional(s)/Department:  David  Chung,  MD 
Sergio  Giralt,  MD 
Heather  Landau,  MD 
Hani  Hassoun,  MD 
Nikoletta  Lendvai,  MD 
Alex  Lesokhin,  MD 
Ephraim  Casper,  MD 
 
Audrey  Hamilton,  MD 
Mila  Gorsky,  MD 
Han Xiao,  MD 
John  Fiore,  MD 
Stuart  Lichtman,  MD 
Steven  Sugarman,  MD 
Arlyn  Apollo,  MD 
Pamela  Drullinsky,   MD 
Zoe Goldberg,  MD 
Kenneth  Ng, MD 
Tiffany  Troso -Sandoval,  MD 
Michelle  Boyar,  MD 
Philip  Caron,  MD,  PhD 
Nancy  Mills,  MD 
Stephanie  Smith -Marrone,  MD 
Carolyn  Wasserheit -Lieblich,  
MD Medicine:  BMT  
Medicine:  BMT  
Medicine:  BMT  
Medicine:  Lymphoma/Myeloma  
Medicine:  Lymphoma/Myeloma  
Medicine:  Lymphoma/Myeloma  
Medicine:  All Network  Sites  
Medicine:  Basking  Ridge  
Medicine:  Basking  Ridge  
Medicine:  Basking  Ridge  
Medicine:  Commack  
Medicine:  Commack  
Medicine:  Commack  
Medicine:  Rockville  Centre  
Medicine:  Rockville  Centre  
Medicine:  Rockville  Centre  
Medicine:  Rockville  Centre  
Medicine:  Rockville  Centre  
Medicine:  Sleepy  Hollow  
Medicine:  Sleepy  Hollow  
Medicine:  Sleepy  Hollow  
Medicine:  Sleepy  Hollow  
Medicine:  Sleepy  Hollow  
 
Please  Note:  A Consenting  Professional  must  have  completed  the mandatory  Human  Subjects  
Education  and Certification  Program . 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
  
 
 
Participating   Institutions  PI's Name  Site's Role 
Montefiore  Medical  Center  Ira Braunschweig,  MD Data Collection  
Weill  Cornell  Medical  College  Tomer  Mark,  MD Data Collection  
North  Shore  LIJ Ruthee -Lu Bayer,  MD Data Collection  
University of Rochester Medical Center Michael  W, Becker  , MD Data Collection  
SUNY  Downstate  Gurinder  Sidhu,  MD Data Collection  
Stamford  Hospital  Michael  Bar, MD Data Collection  
Columbia  University  Medical  Center  Markus  Mapara,  MD Data Collection  
SUNY  Upstate  Teresa  Gentile,  MD Data  Collection  
 
 
Memorial  Sloan -Kettering  Cancer  Center  
1275  York Avenue  
New York,  New York 10065  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
  
 
 
 
Table  of Contents  
1.1 PROTOCOL  SUMMARY  AND/OR  SCHEMA  ................................ ................................ ....................  6 
1.2 Background  and Rational  ................................ ................................ ................................ ...............  6 
1.3 Study  Design  and Objectives  ................................ ................................ ................................ ..........  7 
1.4 Patients  Eligibility  ................................ ................................ ................................ ............................  7 
1.5 Treatment  Intervention  ................................ ................................ ................................ .........................  7 
1.6 Outcome  Measurements  ................................ ................................ ................................ .....................  7 
1.7 Statistical  Considerations  ................................ ................................ ................................ ...............  7 
1.8 Study  Schema  ................................ ................................ ................................ ................................ ............  8 
2.0 OBJECTIVES  AND SCIENTIF  IC AIMS  ................................ ................................ ................................ . 9 
3.1 BACKGROUND  AND RATIONALE  ................................ ................................ ...............................  9 
3.2 Overview  on Upfront  Treatment  of Multiple  Myeloma  ................................ ................................ ... 9 
3.2.1  Initial  therapy  ................................ ................................ ................................ ...............  10 
3.2.2  Autologous  Stem  Cell Transplantation  ................................ ................................ .................  10 
3.2.3  Post Transplant  Maintenance  Therapy  ................................ ................................ ............  10 
3.3 Rationale  for the study  ................................ ................................ ................................ .............  12 
3.3.1  Rationale  for Lenalidomide  Intensification  Dose  ................................ ................................ . 12 
3.3.2  Rationale  for patient population  under  study  ................................ ................................ ....... 13 
4.1 OVERVIEW  OF STUDY  DESIGN/INTERVENTION  ................................ ................................ ... 15 
4.2 Design  ................................ ................................ ................................ ................................  15 
4.3 Intervention  ................................ ................................ ................................ .........................  15 
5.1 THERAPEUTIC/DIAGNOSTIC  AGENTS  ................................ ................................ .................  16 
5.2 Lenalidomide  ................................ ................................ ................................ ......................  16 
5.2.1  Clinical  Pharmacology  ................................ ................................ ................................ ...........  17 
5.2.2  Supplier(s)  ................................ ................................ ................................ ..............................  18 
5.2.3  Dosage  form ................................ ................................ ................................ ....................  18 
5.2.4  Packaging ................................ ................................ ................................ ................  18 
5.2.5  Storage ................................ ................................ ................................ ........................  18 
5.2.6  Prescribing  Information  ................................ ................................ ................................ .... 18 
5.2.7  Pregnancy  Testing  ................................ ................................ ................................ ....... 18 
5.3 Dexamethasone  ................................ ................................ ................................ ......................  19 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 5.3.1  Description  ................................ ................................ ................................ .....................  19 
5.3.2  Form  ................................ ................................ ................................ .......................  19 
5.3.3  Storage  and Stability  ................................ ................................ ................................ ... 19 
5.3.4  Handling  ................................ ................................ ................................ ...........................  20 
5.3.5  Availability  and ordering  ................................ ................................ ..............................  20 
5.3.6  Preparation  ................................ ................................ ................................ .................  20 
6.1 CRITERIA  FOR  SUBJECT  ELIGIBIL  ITY ................................ ................................ .....................  20 
6.2 Subject  Inclusion  Criteria  ................................ ................................ ................................ .........  20 
6.3 Subject  Exclusion  Criteria  ................................ ................................ ................................ ........  21 
7.0 RECRUITMENT  PLAN  ................................ ................................ ................................ ................  21 
8.0 PRETREATMENT  EVALUATION ................................ ................................ ................................  23 
9.1 TREATMENT/INTERVENTION PLAN ................................ ................................ ................................ . 24 
9.2 Treatment  Plan ................................ ................................ ................................ ...................  24 
9.3 Cycle  Delay  and Dose  Modification  Guidelines  ................................ ................................ ....... 25 
9.3.1.  Instruction  for Initiation  of a New Cycle  ................................ ................................ ...............  25 
9.3.2.  Lenalidomide  Dose  Reduction  Guidelines  ................................ ................................ ..........  26 
9.3.3.  Lenalidomide  Dose  Reduction  Levels  ................................ ................................ ...................  28 
9.2.4  Dexamethasone  Dose  Reduction  Guidelines  ................................ ................................ ........  28 
9.2.5  Dexamethasone  dose  reduction  levels  ................................ ................................ ..............  29 
9.3 Supportive  Care  ................................ ................................ ................................ .......................  30 
10.0 EVALUATION  DURING  TREATMENT/INTERVENTION  ................................ ............................  30 
Correlative  Studies  ................................ ................................ ................................ .........................  31 
Schedule  of Study  Assessments  ................................ ................................ ................................ .... 32 
11.1 TOXICITIES/SIDE  EFFECTS  ................................ ................................ ................................ .. 33 
11.2 Expected  Side Effects  of Lenalidomide  ................................ ................................ ......................  34 
11.3 Expected  Side Effects  of Dexamethasone  ................................ ................................ ...............  36 
12.0 CRITERIA FOR THERAPEUTIC RESPONSE/OUTCOME ASSES SMENT ................................ ............  37 
13.0 CRITERIA  FOR  REMOVAL  FROM  STUDY  ................................ ................................ ....................  39 
14.0 BIOSTATISTICS  ................................ ................................ ................................ ...............................  40 
15.1 RESEARCH  PARTICIPANT  REGISTRATION  AND RANDOMIZATION  PROCEDURES  ..........  41 
15.2 Research  Participant  Registration  ................................ ................................ ................................  41 
15.1.1  Research  Participant  Registration  for Collaborating  Sites  ................................ .................  41 
15.3 Randomization  ................................ ................................ ................................ .........................  42 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 16.1 DATA  MANAGEMENT  ISSUES  ................................ ................................ ................................ ....... 42 
16.1.1  Data and Source  Documentation  for Collaborating  Sites  ................................ ......................  42 
16.1.2  Data and Source  Documentation  Submission  for Participating  Sites  ................................ .... 43 
16.1.3  Data and Source  Documentation  Submission  Timelines  for Participating  Sites  ....................  43 
16.1.4  Data Review  and Queries  for Participating  Site Data ................................ ................................ .... 43 
16.2 Quality  Assurance  ................................ ................................ ................................ ....................  44 
16.2.1  Investigator  responsibilities  ................................ ................................ ................................ .. 44 
16.2.2  Retention  of Records  ................................ ................................ ................................ ...........  44 
16.2.3  Quality  Assurance  for Participating  Sites  ................................ ................................ ................  45 
16.2.4  Response  Review  ................................ ................................ ................................ ...............  45 
16.3 Data  and Safety  Monitoring  ................................ ................................ ................................ ..........  46 
16.4 Regulatory  Documentation  ................................ ................................ ................................ .........  46 
16.4.1  Amendments  ................................ ................................ ................................ .......................  47 
16.4.2  Additional  IRB Correspondence  ................................ ................................ ..........................  47 
16.4.3  Document  maintenance  ................................ ................................ ................................ ....... 48 
16.5 Noncompliance  ................................ ................................ ................................ ..........................  48 
17.1 PROTECTION  OF HUMAN  SUBJECTS  ................................ ................................ .....................  48 
17.2 Privacy ................................ ................................ ................................ ...............................  49 
17.3 Serious  Adverse  Event  (SAE)  Reporting  ................................ ................................ .................  49 
17.2.1  Reporting  SAE to Study  Supporter  (Celgene  Corporation)  ................................ .................  51 
17.4 Serious  Adverse  Event  (SAE)  Reporting  for Participating  Sites  ................................ ...............  52 
17.5 Safety  Reports  ................................ ................................ ................................ ............................  53 
18.1 INFORMED  CONSENT  PROCEDURES  ................................ ................................ .........................  55 
18.2 FOR PARTICIPATING  SITES  ................................ ................................ ................................  55 
19.0 REFERENCES  ................................ ................................ ................................ ................................ .. 56 
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
  
 
1.0 PROTOCOL  SUMMARY  AND/OR  SCHEMA  
 
1.1 Background  and Rational  
 
The standard  first line therapy  for patients  with multiple  myeloma  includes  2 phases:  An initial  
treatment,  which  usually  consists  of a combination  of several  drugs  given  for 3 to 6 cycles,  followed  
by consolidation  with autologous  stem  cell transplantation  using high dose  melphalan  (HDM/ASCT).  
In recent  years,  the HDM/ASCT  consolidation  phase  has often  been  replaced  by a continuous  
phase,  in which  some  or all the drugs  used  as initial  treatment  are continued  beyond  the initial  3-6 
cycles.  Lenalidomide  is often  chosen  for this continuous  phase,  due to its convenient  oral 
administration,  becoming  a continuous/maintenance  treatment.  In additions,  two major  large  studies  
recently  presented  at the ASCO  and ASH meetings  in 2010,  have  emphasized  the role of 
maintenance  therapy  with low dose  lenalidomide  after HDM/ASCT.  Both studies  have  shown  a 
statistically  significant  improvement  in the progression free survival  for patients  receiving  
maintenance  therapy  with low dose  lenalidomide after HDM/ASCT.  Although  the improvement  in 
overall  survival  is currently  not fully established  (there  is a trend  toward  increased  OS), it is clear  at 
this time that maintenance  therapy  post HDM/ASCT  has been  widely  adopted  by myeloma  experts.  
Therefore,  most  patients  who initiate  therapy  for multiple  myeloma  will remain  on maintenance  
therapy  with low dose  lenalidomide  as part of their initial  treatment.  
 
However,  most  of these  patients  will eventually  progress  while  on lenalidomide  therapy.  Patients  
with “symptomatic  progression  of disease  (POD)”  defined by new symptomatic  bone  lesions,  
progressive  anemia,  hypercalcemia,  or progressive  renal  failure  attributable  to the multiple  
myeloma,  usually  in association  with a rise in the serum  or urine  paraprotein,  will require  re- 
induction  therapy  with combination  chemotherapy  to prevent  further  organ  deterioration.  
However,  the subset  of patients  with “serologic  or asymptomatic  POD”,  i.e. whose  only evidence  
of disease  progression  is an increase  in the paraprotein  level by > 25% above  plateau  baseline,  
have  a variable  natural  history  with many  patients  not showing  symptomatic  progression  for 
months.  Based  on the results  of the initial  phase  I trial of lenalidomide  in which  higher  responses  
were  seen  with higher  doses  of lenalidomide,  we hypothesize  that in patients  relapsing  on 
lenalidomide  maintenance  doses  of 5-15 mg orally  daily,  the disease  could  be brought  under  
control  by increasing  the dose  of lenalidomide  (intensification)  to 25 mg. However,  the response  
rates  and tolerance  of lenalidomide  dose  intensification  in the setting  of lenalidomide  
maintenance  is unknown,  which  is the basis  for the proposed  clinical  trial. 
 
For the purpose  of clarity,  the term asymptomatic  POD will be used  henceforward  to designate  
serologic  only POD,  while  symptomatic  POD  will be used  to designate  POD  associated  with 
progression  of organ  damage.  
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 1.2 Study  Design  and Objectives  
 
The proposed  study  is designed  as a Phase  II, multi-center  trial of lenalidomide  intensification  in 
patients  with asymptomatic  POD  while  on low dose  lenalidomide maintenance after HDM/ASCT  
or as continuous/maintenance  therapy  after initial  treatment.  The primary  objective  of this trial is 
to determine  the overall  response  rate (ORR)  at 6 months  and the toxicity  of lenalidomide  
administered  at a dose  of 25 mg orally,  days 1 to 21 of a 28 day-cycle,  without  or with 
dexamethasone  added  after 2 cycles,  in patients  with multiple  myeloma  found  to have  
asymptomatic  POD  while  on a maintenance  lenalidomide  dose  of 15 mg daily or less. 
 
 
1.3 Patients  Eligibility  
 
Patients  with multiple  myeloma  with evidence  of asymptomatic  POD while  on lenalidomide  
maintenance  post HDT/ASCT  or on continuous/maintenance  therapy  as part of first line therapy  
will be eligible  to participate  in this trial. Patients  will need  to have  progression  of disease  
documented  as defined  by modified  IMWG  criteria  and will have  no evidence  of progression  of 
organ  damage  (progression  of severe  anemia,  renal  failure,  hypercalcemia,  bone  disease).  
 
1.4 Treatment  Intervention  
 
After  registration  patients  will begin  therapy  with lenalidomide  25 mg daily,  21 days  out of a 28 
day schedule.  All patients  will be evaluated  monthly  after every  cycle.  The dose  will be adjusted  
downward  in response  to side effects  and according  to specific  guidelines.  Symptomatic  POD  
occurring  at any time during  the study  will result  in removal  of the patient  from the study.  After 2 
cycles  of lenalidomide,  patients  with at least stable  disease  (SD) will continue  lenalidomide  
indefinitely  until asymptomatic  POD,  at which  time dexamethasone  will be added  at a dose  of 
40mg  weekly.  On the other hand,  patient  with asymptomatic  POD  after 2 cycles  of lenalidomide  
will have  dexamethasone  added  at a dose  of 40 mg weekly.  Patients  with any type of POD  after 
any cycle  that includes  dexamethasone  will be taken  off study.  Patients  can remain  on study  on 
lenalidomide  or lenalidomide/dexamethasone  indefinitely  as long as they do not have  POD  as 
stated above and they tolerate the treatment. 
 
1.5 Outcome  Measurements  
 
The response  to treatment  intervention  will be measured  using  a modified  version  of the widely  
accepted  Uniform  International  Response  Criteria  in multiple myeloma.  To determine   
response,  patients’  disease  will be assessed  at the beginning  of every  cycle  and compared  to 
the new baseline  established  within  two weeks  prior to initiation  of lenalidomide  intensification.  
 
1.6 Statistical  Considerations  
 
The focus  of this study  is to estimate  the overall  response  rate (>PR) to lenalidomide  
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 intensification  with or without  dexamethasone  at 6 months.  A single  stage  design  that 
differentiates  between  response  rates  of 15% and 30% will be used  to assess  efficacy  of 
lenalidomide  intensification  with or without  dexamethasone.   The probabilities  of a type I error  
(falsely  accepting  a non-promising  therapy)  and type II error  (falsely  rejecting  a promising  
therapy)  are set to 0.10 and 0.10,  respectively.   The null hypothesis  response  rate is based  on 
the response  rate to the standard  of care therapy  in patients  previously  exposed  to  
thalidomide  who have  relapsed  or refractory  disease.  A total of 53 patients  will be accrued.   At 
the conclusion  of the study,  if a least 12 of the 53 patients  respond  by 6 months  the treatment  
will be declared  a success.  
 
 
1.7 Study  Schema  
 
 
 
 
*Note  that patients  with symp  tomatic  
POD  after any cycle  will be taken  off 
study 
 
 Off Trial Start  Lenalidomide  25 mg Orally  21/28days  
Asymptomatic  POD  
after  2 cycles  > SD after 2 cycles  
Continue  Lenalidomide  
orally,  daily,  21/28  days  
until asymptomatic  POD  
Asymptomatic  POD  Patients  with MM meeting  the following  eligibility  criteria:  
 
1. On maintenance  lenalidomide  as part of initial   line of 
therapy  
 
2. With asymptomatic  POD  and no active  organ damage  
Add dexamethasone  40mg  
weekly  until asymptomatic  POD  
  
 Asymptomatic  POD  
after  any cycle   
  
 
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 2.0 OBJECTIVES  AND  SCIENTIFIC  AIMS  
 
Primary  objective:  
 
 To determine  the overall  response  rate (CR, VGPR,  PR, and MR) after 6 months  of 
lenalidomide  intensification  administered  initially  at a dose  of 25 mg orally  days 1 to 21 of a 
28 day-cycle,  with or without  the addition  of dexamethasone,  in patients  with multiple  
myeloma  found  to have  asymptomatic  progression  of their disease  while  on maintenance  
lenalidomide  dose  of 15mg  mg daily or less. 
 
Secondary  objectives:  
 
  To determine  rates  of > Grade  2 toxicity  according  to the Common  Terminology  Criteria  for 
Adverse  Events  (CTCAE)  Version 4.0 
  To determine  the overall  response  rate (CR, VGPR,  and PR) at 6 months  from initiation  of 
lenalidomide  intensification  therapy  of lenalidomide  given  as a single  agent.  
  To determine  progression  free survival:  The PFS is defined  as the time from registration  to 
relapse/progression,  death,  initiation  of non-protocol  anti myeloma  therapy,  loss to follow  up 
or end of study  whichever  comes  first. 
  To determine  OS:  The OS is defined  as the time from registration  to death,  loss to follow -up 
or the end of the study,  whichever  comes  first.  Patients  alive at the time of last observation  
are considered  censored.  
 
 
3.0 BACKGROUND  AND  RATIONALE  
3.1 Overview  on Upfront  Treatment  of Multiple  Myeloma  
 
Multiple  myeloma  (MM)  is a disease  characterized  by a malignant  plasma  cell proliferation,  bone  
destruction  and immunodeficiency.  Median  age at diagnosis  is approximately  70 years.   It is 
responsible  for about  1 percent  of all cancer -related  deaths  in Western  Countries.1-3 The disease  
accounts  for an estimated  15,000  new cancer  cases  per year in the United  States,  as well as 
approximately  11,000  deaths2.  Based  on the United  Kingdom (UK) Myeloma  Forum  and the 
Nordic  Myeloma  Study  Group recommendations1 and National  Comprehensive  Cancer  Network  
(NCCN)  Practice  Guidelines4, chemotherapy  is indicated  for the management  of myeloma  
presenting  with myeloma -related  organ  damage (referred  to as symptomatic  myeloma as   
opposed  to asymptomatic  myeloma).  Standard first  line treatment  for patients  with symptomatic  
multiple  myeloma  deemed  eligible  for transplantation,  consists  of 2 phases  of treatment:  The first  
is referred  to as the initial  therapy  and consists  of various  combinations  of therapeutic  agents.  The 
second  consists  of high dose  melphalan  followed  by autologous  stem  cell transplant  
(HDM/ASCT)5,6. Attempts  to cure myeloma  through  high-dose therapy  followed  by autografting  or 
even  allografting  have  largely  failed  due to both relapsed disease  and treatment -related  mortality 
(TRM).Although  high-dose  therapy  with autologous  transplantation  is safe and has low TRM  (< 
5%), it is associated  with a continuing  and nearly  universal  risk of disease  relapse  and 
progression.   Therefore,  despite  the potential  benefits  of newer  treatments,  multiple  myeloma  
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 remains  an incurable  disease  and relapse  occurs  in almost  all patients,  with a median  survival  
period  of 5 to 7 years5,6. 
3.1.1  Initial  therapy  
 
The regimens  currently  recommended  in the NCCN  guidelines  for initial  therapy  of MM in patients  
who are candidates  for HDM/ASCT  include  dexamethasone,  thalidomide  and dexamethasone,  
Lenalidomide  and dexamethasone,  liposomal  doxorubicin.  Vincristine  and dexamethasone  (DVD),  
as well as several  bortezomib  based  regimens4. In previously  untreated  patients,  bortezomib  has 
shown  activity  as a single  agent7-9 and also in combination  with dexamethasone7,10, 
thalidomide/dexamethasone11,12, melphalan/prednisone  (MP)13,14, dexamethasone  and 
adriamycin15,16  as well as Lenalidomide  and dexamethasone.   It is widely  accepted  that in patients  
who will undergo  HDM/ASCT,  melphalan -containing  regimens  should  be avoided  since  stem  cell 
collection  may be subsequently  hampered.  
 
 
3.1.2  Autologous Stem Cell Transplantation 
 
There  have  been  two large  prospective  trials in France  (IFM 90) and in UK (MRC  9), and one 
large  retrospective  study  of myeloma  patients  in Nordic  countries,  showing a survival  benefit  for 
HDM/ASCT  compared  to conventional  chemotherapy17-19. In the larger  study,  IFM 90, newly  
diagnosed  untreated  patients  less than 65 years  of age with DS stage  II or III MM were  
randomized  to either  SCT after up to 6 cycles  of VMCP  alternating  with BCNU,  vincristine,  
doxorubicin  and prednisone  (BVAP)  or conventional  chemotherapy  with 18 cycles  of VMCP  
alternating  with BVAP.  The SCT regimen  was MEL 140 mg/m2  and TBI, and recombinant  
interferon  alpha  (IFNα) was administered  to patients  in both groups  until relapse.  By intent -to- 
treat,  SCT patients  had a significantly  higher  response  rate (CR+VGPR  38% versus  14%)  than 
those  receiving  conventional  chemotherapy.  At a median follow -up of 37 months  in the 
chemotherapy  group  and 41 months  in the SCT group,  the latter  had significantly  longer  PFS and 
OS.  The other  two studies  have  confirmed  these  results  although  the dose  of melphalan  given  
was 200 mg/m2 and radiation  therapy  was not used.  Based on these  trials,  autologous  stem  cell 
transplantation  using  melphalan  200 mg/m2 has become  part of the standard  treatment  of 
symptomatic  multiple  myeloma.  Smaller  studies  have  reached  similar  conclusions6,20. 
Although  HDM/ASCT  has improved  response rate6,17,18,20  and overall  survival17,18,20,21  rate in 
patients  with MM, all patients  eventually  relapse.  Clinical  trials have  investigated  the use of 
consolidation22 and maintenance23-26 therapy  post-transplant  to extend  the duration  of response.  
 
3.1.3  Post Transplant Maintenance Therapy 
 
One approach  to improving  disease  control  after HDM/ASCT  is the use of post-transplant  
interventions,  such as interferon  and, more  recently,  anti-angiogenic  agents  such as thalidomide  
and lenalidomide.  The use of thalidomide as post-transplant  maintenance has been  studied  in 
several  randomized  trials24,25,27.  The IFM 99-02 trial randomized  patients  after tandem  
autologous  transplantation  (using  melphalan  140mg/m2 for the first and melphalan  200mg/m2 for 
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 the second  transplant)  to either  no maintenance,  maintenance  with pamidronate  or maintenance  
with thalidomide  and pamidronate.   Patients  received  thalidomide  for a median  of 15 months.  
The major  treatment -related  side effect  was neuropathy  (68%  of patients).   Patients  who received  
thalidomide  had improved  EFS and OS.  Of note,  patients  who achieved  a VGPR  after 
transplantation  did not benefit  from thalidomide  maintenance27.  This suggests  that the benefit  of 
post-transplant  thalidomide  might  result  from upgrading  responses.  
New immunomodulatory  drugs  (IMiDs®)  such  as lenalidomide are now commonly  used  in clinical  
practice.   The side effect  profile  of lenalidomide  is superior  to that of thalidomide.   In normal  
volunteers  the most  common  adverse  events  with lenalidomide  are rash and pruritus.   Phase  II 
trials  of lenalidomide plus dexamethasone  for upfront  therapy  of myeloma demonstrate  high 
response  rates11. Lenalidomide,  a member  of the new immunomodulatory  class  of drugs  has 
recently  demonstrated  high-response  rates  and favorable  side effect  profile  in upfront  and salvage  
trials28,29.  A Phase  II trial at the Mayo  Clinic  used  lenalidomide  and dexamethasone  as induction  
therapy.  The overall  response  rate was 91%.  The Phase  III MM009  trial of lenalidomide  and 
dexamethasone  versus  dexamethasone  alone  for relapsed/refractory  MM reported  response    
rates  of 61% with combination  therapy  compared  to 22% with dexamethasone alone.29 Hence,  
based  on both a more  favorable  side effect  profile  and higher  CR rates,  lenalidomide  appears  to 
be a superior drug for maintenance  therapy.  
 
In 2010  two large  randomized  trials were  presented  both in the meeting  of the American  Society  of 
Clinical  Oncology  in Chicago  and the meeting  of the American  Society  of Hematology  in Orlando  
exploring  the use of single  agent  lenalidomide  as post transplant  maintenance  therapies.  
McCarthy  et al. presented  the results  of CALGB  100104  whose  primary  endpoint  was to 
investigate  the role of maintenance  lenalidomide  in prolonging  time to progression  (TTP) following  
single  autologous  SCT.30 Patients  with chemosensitive  disease  after an initial  autologous  SCT 
were  randomized  at day 100-110 post-ASCT  to lenalidomide  10 mg/day  or placebo  until disease  
progression.  A total of 554 patients  were registered  during  the third interim  analysis,  and 33% of 
the required  number  of events  (progression  or death  before  progression) had been  observed.  The 
median  follow -up is 17.5 months.  The number of events  among  231 pts randomized  to 
lenalidomide  was 37 compared  to 84 among 229 pts randomized  to placebo.  The one-sided  
unadjusted  P-value  was < 0.0001.  The estimated  hazard  ratio was 0.35 (95%  CI=0.24,  0.53)  
corresponding  to a 65% reduction  in event  risk (progression  or death)  in the lenalidomide  arm. 
The estimated  median TTP was 22.5 months  for the placebo  arm. The preliminary  estimated  
median  TTP was 45.5 months  for the study  arm. Benefits  were seen  regardless  of whether  patients  
received  lenalidomide or thalidomide as induction  therapy.  Comparing  lenalidomide  versus   
placebo,  post-randomization,  pooled  Gr 3-5 AEs, there  were  significantly  more  episodes  of 
thrombocytopenia (11%  versus  3%, p=0.01),  neutropenia  (44%  vs 8%, p<0.0001)  and anemia  
(5% vs 1%, p=0 .0082)  with lenalidomide.  No significant  differences  in incidence  of febrile  
neutropenia,  infection,  fatigue,  neuropathy,  rash,  thromboembolic  events  were  seen.  
Lenalidomide  patients  discontinued  therapy  due to AEs more  frequently  than placebo (13%  vs 
2%). Attal et al. presented  the results  of a similar  trial performed  by the Intergroup  Francophone  
du Myelome that  enrolled  614 patients  who had undergone  autologous  stem  cell transplantation  
for non-progre ssive  myeloma  within the previous  six months31. Patients  were  randomly  assigned  
to placebo  (307 patients)  or 10 mg to 15 mg of lenalidomide  daily (307 patients)  until relapse.  
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 After  a median  follow -up of 24 months,  only 25% of the lenalidomide  group  experienced  
progression  or death  compared  with 47% of the placebo  group.  Maintenance  with lenalidomide  
improved  three - year PFS from randomization  by 34% in the placebo  group  compared  with 68% in 
lenalidomide  group  (HR=0.46).  Benefits  were  seen regardless  of response  to induction  therapy10. 
These  2 studies  have  consolidated  the role of maintenance  therapy,  in particular  lenalidomide,  
after autologous  stem  cell transplantation.   It is unknown  whether  use of post-transplant  
maintenance  lenalidomide  until disease  progression  will provide  similar  EFS and OS to either  
tandem  transplantation  or a single transplant  followed  by consolidation  and maintenance.  This is 
currently  being  actively  investigated.  However,  maintenance  therapy  with low dose  lenalidomide  
has been  widely  embraced  and most patients  will be receiving  this treatment  following  
HDM/ASCT.  
 
3.2 Rationale  for the study  
 
As mentioned  above,  all patients  with multiple  myeloma  treated  with the currently  available  
treatment  modalities  and strategies  will eventually  relapse.  Patients  on maintenance  lenalidomide  
are no exception  to this rule. However,  it is currently  unknown  whether  these  patients  whose  
disease  progress,  while  on low dose  lenalidomide  as maintenance  therapy,  will respond  to 
treatment  with higher  doses  (considered  standard  doses,  but for the purpose  of this trial referred  to 
as intensification)  of lenalidomide.  Currently  it is widely  perceived  among  physicians  that these  
patients  have  a disease  that is lenalidomide  resistant  and there  is an actual  risk of these  patients  
being  denied  access  to a potentially  very effective  agent,  if given  at higher  (standard)  dose.  
 
3.2.1  Rationale for Lenalidomide Intensification Dose 
 
The maximum  tolerated  dose  (MTD)  of lenalidomide  as a daily dose  is 25 mg with dose -limiting  
toxicity  (DLT)  being  grade  3/4 myelosuppression.  The Phase  I trial of single  agent  lenalidomide  
demonstrated  higher response  rates  with increasing  dosage  with 20%,  66%,  and 69% of patients  
having  at least a minimal  response  when  receiving  10 mg, 25 mg, and 50 mg respectively32. Based  
on the pharmacokinetic  data of the phase  I trial, and the favorable  toxicity  profile  observed,  a 
randomized  Phase  II study  has been  reported  that examined  a higher  dose  with an interrupted  
schedule:  15 mg twice  daily versus  30 mg daily on a 3 weeks  on / 1 week  off schedule  33. This 
study  examined  70 patients  randomized  to the two schedules.   Fifty-seven  patients  were  analyzed  
for toxicity  and 46 for response.   In this heavily  pre-treated  group  of patients,  24% had a CR or 
PR or minimal  response  and only 16% had progressive  disease.   One patient  developed  grade  3 
neuropathy.   The most common  grade  1 and 2 toxicities  were  fatigue,  self-limited  rash,  muscle  
cramps  and diarrhea.   Grade  3 or 4 myelosuppression  was seen  in 26% (n=15)  of patients.  Eleven  
of these  15 patients  had undergone  a prior autologous  transplant;  most  (n=11)  were  on the 15 mg 
twice  a day dose.   The daily dosing  schedule  was felt to be more  favorable  based  on its toxicity  
profile  and simplicity  of administration  with best opportunity  for compliance.   There  was no 
evidence  that an interrupted  schedule  enhanced  long-term tolerability  or response.  Thus,  there  is 
data supporting  the dose related  response  to lenalidomide and its optimal  efficacy/tolerability  ratio 
with 25 mg given  daily for 21 days every  28 days.  
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
  
3.2.2  Rationale  for patient  population  under  study  
 
 
3.2.2.1  Relapse Patterns Post-Autologous Stem Cell Transplantation 
 
The two largest  reports  of the natural  history  of relapse  post autograft  in myeloma  were  both 
reported  prior to the advent  of lenalidomide  and bortezomib.  Alegre  et al. reported  on the 
outcomes  of 280 patients  who had relapsed  after transplantation  and had data available  in the 
Spanish  registry34. The clinical  patterns  of relapse  fell into one of four categories:  
a) Insidious  relapse  characterized  by asymptomatic  elevations  of the blood  or urine  protein  
occurred  in 18% of patients.  
b) Classic  relapse  characterized  by an increase  in monoclonal  component  along  with clinical  
symptoms  occurred  in 66% of patients  
c) Plasmacytomas  occurred  in 14% of patients  and was characterized  by presentation  with 
multiple  extramedullary  plasmacytomas.  
d) Plasmacytic  leukemia   as the  initial  clinical  manifestation  of relapse  occurred   in 2% of 
patients.  
 
Median  overall  survival  after relapse  was 14 months  for the whole  group  with a significant  
difference  in the OS of patients  with the insidious  form of relapse  when  compared  to those  with 
symptomatic  or plasma  cell leukemia  patterns  of relapse  (18 months  vs 12 months  v/s 5 months  
respectively;  p < 0.001).  
 
Lenhoff  et al. reviewed  the outcomes  of 397 patients  who had relapsed  after autologous  
transplantation  between  1994  and 199735.  The patterns  of relapse  after transplantation  were  
classified  based  on a modification  of a model  presented  by Alegre  et al. The insidious  pattern  
accounted  for 31% , the classical  pattern  for 51%,  and the plasmacytoma  pattern  for 14% of all 
relapses  and characterized  by bone  marrow  or extramedullary  plasmacytoma  with minor  or no 
other  signs  of relapse  and finally  transformed  disease  which  accounts  for 4% of  relapses  and 
presents  as plasma  cell leukemia  or immunoblastic  lymphoma.  No association  was found  
between  the pattern  of relapse  and any of the clinical  features  at diagnosis.  The insidious  form of 
relapse  was significantly  less common  in patients  who had attained  complete  response  after 
transplantation  than in patients  who had not (17%  versus  40% of the relapses,  respectively).  
Patients  who relapsed  with transformed  disease had a significantly  shorter  duration  of first 
response  after transplantation  (median 3 months)  compared  to patients  relapsing  with an 
insidious  (median 20 months),  classical  (median  20 months)  or plasmacytoma  (median  24 
months)  pattern.  Survival  was related  to the type of relapse  and longest  in patients  with the 
insidious  pattern  (median  39 months)  and shortest  in patients  with transformed  disease  (median  
2 months).  Patients  with the classical  pattern  of relapse  were  subdivided  into two groups;  those  
with skeletal  clinical  symptoms  only at relapse  (n=46)  and those  with additional  symptoms  such  
as cytopenias,  hypercalcemia,  renal  insufficiency,  etc. (n=37).  Patients  with only skeletal  
symptoms  had a median  survival  after relapse  of 30 months,  while  those  with additional  
symptoms  had a significantly  shorter  median  survival  of 18 months.  
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 Patients  relapsing  with an insidious  or classical  form of disease  with skeletal  events  only, or after 
a long lasting  first response  were likely  to respond  well to conventional  salvage  therapy.  In 
contrast,  relapse  with multiple  symptoms,  transformed  disease  or a short  duration  of first 
response  implied  bad prognosis.  Of the 162 patients  who relapsed  49% received  a melphalan  
based  salvage  regimen  with 59% having  at least a 25% reduction  in tumor  burden,  34% received  
a VAD like re-induction  with a 46% response  rate, 8% received  thalidomide  with a 67% response  
rate and 8% received  a second  autograft  as salvage  therapy   with an 83% response  rate. 
Response  to relapse  therapy  was important  for survival  after relapse.  Patients  with a partial  
response  or better  to relapse  therapy  had a median  survival  of 36 months  vs 37 months  for minor  
responders  and 8 months  for nonresponders.  The median survival  after start of relapse  therapy  
was 33 months  for complete  and partial  responders  and 26 months  for minor  responders  and 7 
months  for non responding  patients.  Sixty-one patients  have  been  treated for subsequent.  
More  recently  Kumar  et al reported  on the outcomes  of patients  relapsing  after autologous  
transplant  in the era of lenalidomide and bortezomib  therapy36. Among 494 patients,  undergoing  
auto-SCT within  12 months  of diagnosis  they identified  124 patients  who had relapsed  within  12 
months  of high dose  therapy,  this group  had a significantly  shorter  median overall  survival  (OS)  
from diagnosis  (26.6  vs 90.7 months)  and from SCT than those  relapsing  later in the course  of 
their disease.  Median  survival  from relapse  was only 10.8 months  in the early  relapse  group  
compared  to 41.8 months  for the rest. Among  the 97 patients  who relapsed  early  after transplant,  
patients  who received  thalidomide,  bortezomib  and/or  lenalidomide)  had a better survival  than 
those  that did not receive  those  drugs  15.9 months  vs 4.5 months.  Benefits  of exposure  to 
lenalidomide,  bortezomib  or thalidomide  were  confirmed  in a larger  series  of 387 patients  reported  
by the same  authors.  Those  relapsing  after the year 2000  had a median  overall  survival  of 23.9 
versus  11.8 months  (P < .001)  for those  who relapsed  prior to this date.  Patients  treated  with 
thalidomide,  lenalidomide,  or bortezomib  had longer  survival  from relapse  (30.9  vs 14.8 months;  P 
< .001)37. 
 
With the results  of CALGB100104  and IFM05  it is likely  that many  patients  will now be relapsing  
on lenalidomide  maintenance  which  consists  of lower  doses  of lenalidomide  without  
dexamethasone.   Based  on the results  of the phase  I study  of lenalidomide  we hypothesize  that 
intensifying  the dose  of lenalidomide  could  potentially  re-establish  control  of the disease  in up to 
30% of  myeloma  patients  with asymptomatic  relapses,  therefore  saving  the use of other  agents  
for future  use. 
 
3.2.2.2  M SKCC Experience with Relapse after HDM/ASCT 
 
We have  recently  reviewed  the pattern  of relapse  in 40 patients  who have  participated  in CALGB  
100104  clinical  trial and enrolled  at MSKCC  between  2005  and 2009.  Among  these  40 patients,  
relapse  from CR or progression  has occurred  in 16 patients.  The first evidence  for 
relapse/progression  was detected  by Immunofixation  in four patients  who were  in CR; SPEP  with 
increase  in M spike  in five patients  (3 who were in PR and 2 in VGPR);  and free light chain  assay  
in five patients  (four who were  in CR and one in PR). Only two among  the 16 patients  were found  
to have  relapse/progression  of disease  after development  of symptoms  due to organ  damage,  
triggering  an evaluation  by MRI that lead to the diagnosis  of relapse/progression.  This data would  
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 indicate,  contrary  to the previous  two reports  detailed  above  by Lenhoff  et al. and Alegre  et al., that 
asymptomatic  relapse  (referred  to as insidious  relapse  by these  authors) is currently  the most  
common  pattern  of relapse  nowadays.  This is most likely  related  to the availability  of the free light 
chain  assay  which  allows  earlier  detection  of disease  relapse  and progression.  In addition,  the 
prospective  aspect  of the CALGB  100104  clinical  trial that called  for a rigorous  monitoring  of the 
patients  every  three  months,  certainly  contributed  to the earlier  detection  of relapse  and 
progression  prior to the development  of organ  damage.  Despite  the small  sample  of this 
observation,  we are confident  that the most  common  form of relapse  and/or  progression  in patients  
receiving  maintenance  therapy  after HDM/ASCT  is asymptomatic.  Hence,  we anticipate  that  
patient  recruitment  within  this population  will be facilitated.  
 
 
4.0 OVERVIEW OF STUDY DESIGN/INTERVENTION 
 
4.1 Design  
 
In this multi-center  Phase  II single  arm trial, 53 patients  fulfilling  the eligibility  criteria,  will be  
treated  with lenalidomide  25 mg PO daily for 21 out of 28 day cycles.  The patients’  responses  to 
the treatment  will be assessed  after every  cycle.  Patients  who have  asymptomatic  POD  after 2 
cycles  will have  dexamethasone  added  at a dose  of 40 mg PO weekly.  Patients  who have  at least 
SD after 2 cycles  will continue  lenalidomide  single  agent  until asymptomatic  POD,  at which  time 
they will have  dexamethasone  added  at a dose  of 40 mg PO weekly.   Patients  will be taken  off 
study  if they have  symptomatic  POD  after any cycle,  if they have  any type of POD  after 
dexamethasone  is added,  or if they do not tolerate  the treatment.  The patients  taken  off study  due 
to any type of POD,  will be considered  failures  for the primary  response  endpoint  if progression  
occurred  within  6 months.   Patients  who are removed  from study  prior to completing  2 cycles  of 
therapy  for reasons  other  than POD  will be considered  inevaluable  for response  and will be 
replaced.  Accrual  will continue  until 53 evaluable  patients  have  been  accrued.   Patients  who have  
received  any study  drug will be evaluated  for safety.  
 
4.2 Intervention  
 
Patients  with asymptomatic  POD  while  on maintenance  lenalidomide  after HDM/ASCT  or on 
continuous/maintenance  therapy  after initial  treatment  will be enrolled  on this clinical  trial and will 
undergo  the following  interventions:  
 
  Patients  will have  their disease  fully reassessed  in order  to establish  a new pre- 
therapy  baseline  within  2 weeks  of initiation  of treatment.  
  Patients  will receive  lenalidomide  at a dose  of 25 mg PO daily for 21 days out of 
28-days-cycles.  
  Patient  will be evaluated  for response  and toxicity  after every  cycle.  
  Patients  with at least SD after 2 cycles  of lenalidomide  will continue  on 
lenalidomide until asymptomatic  POD,  at which  time dexamethasone  
will be added  at a dose  of 40 mg PO weekly  at the next cycle.  
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 
  Patients  with asymptomatic  POD  after 2 or more  cycles  of lenalidomide  will have  
dexamethasone  added  to lenalidomide  at a dose  of 40 mg PO weekly  at the next 
cycle.  
  Patients  with further  asymptomatic  POD  after at any cycle  of lenalidomide  and 
dexamethasone  will be taken  off study  and treated  at the discretion  of the 
treating  physician.  Note that further  POD  after the addition  of dexamethasone  
will be determined  compared  to the new M spike  baseline  just prior to the 
addition  of dexamethasone.  
  Note that patients  with symptomatic  POD  at any point  in time during  treatment  will 
be taken  off study.  
 
 
5.0 THERAPEUTIC/DIAGNOSTIC  AGENTS  
 
5.1 Lenalidomide  
 
Lenalidomide,  a thalidomide  analogue,  is an immunomodulatory  agent  with anti-angiogenic  
properties.   The chemical  name  is 3-(4-amino -1-oxo 1,3-dihydro  -2H-isoindol -2-yl) piperidine -2,6- 
dione  and it has the following  chemical  structure:  
 
Chemical  Structure  of Lenalidomide  
 
 
O O H 
N 
N O 
 
NH2 
 
3-(4-amino -1-oxo 1,3-dihydro -2H-isoindol -2-yl) piperidine -2,6-dione  
 
The empirical  formula  for lenalidomide  is C13H13N3O3, and the gram  molecular  weight  is 259.3.  
 
Lenalidomide  is off-white  to pale-yellow  solid powder.  It is soluble  in organic  solvent/water  
mixtures,  and buffered  aqueous  solvents.  Lenalidomide  is more  soluble  in organic  solvents  and 
low pH solutions.  Solubility  was significantly  lower  in less acidic  buffers,  ranging  from about  0.4 to 
0.5 mg/ml.  Lenalidomide  has an asymmetric  carbon  atom  and can exist as the optically  active  
forms  S(-) and R(+),  and is produced  as a racemic  mixture  with a net optical  rotation  of zero.  
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 5.1.1  Clinical  Pharmacology  
 
Mechanism  of Action:  
The mechanism  of action  of lenalidomide  remains  to be fully characterized.  Lenalidomide  
possesses  immunomodulatory  and antiangiogenic  properties.   Lenalidomide  inhibited  the 
secretion  of pro-inflammatory  cytokines  and increased  the secretion  of anti-inflammatory  
cytokines  from peripheral  blood  mononuclear  cells.   Lenalidomide  inhibited cell proliferation with 
varying  effectiveness  (IC50s)  in some  but not all cell lines.   Of cell lines tested,  lenalidomide  was 
effective  in inhibiting  growth  of Namalwa  cells (a human  B cell lymphoma  cell line with a deletion  
of one chromosome  5) but was much  less effective  in inhibiting  growth  of KG-1 cells (human  
myeloblastic  cell line, also with a deletion  of one chromosome  5) and other  cell lines without  
chromosome  5 deletions.   Lenalidomide  inhibited  the expression of cyclooxygenase -2 (COX-2) 
but not COX-1 in vitro.  
 
Pharmacokinetics  and Drug Metabolism:  
 
Absorption:  
 
Lenalidomide,  in healthy  volunteers,  is rapidly  absorbed following  oral administration with 
maximum  plasma  concentrations  occurring  between  0.625  and 1.5 hours  post-dose.  
Co-administration  with food does  not alter the extent  of absorption  (AUC)  but does  reduce  the 
maximal  plasma  concentration  (Cmax)  by 36%.  The pharmacokinetic  disposition of lenalidomide  
is linear.  Cmax  and AUC increase  proportionately  with increases  in dose.  Multiple  dosing  at the 
recommended  dose -regimen  does  not result  in drug accumulation.  
 
Pharmacokinetic  analyses  were  performed  on 15 multiple  myeloma  patients  treated  in the phase  I 
studies.   Absorption  was found  to be rapid  on both Day 1 and Day 28 with time to maximum  blood  
levels  ranging  from 0.7 to 2.0 hours  at all dose  levels  (5mg,  10mg,  25mg,  and 50mg).   No plasma  
accumulation  was observed  with multiple  daily dosing.   Plasma  lenalidomide  declined  in a 
monophasic  manner  with elimination  half-life ranging  from 2.8 to 6.1 hours  on both Day 1 and 28  
at all 4 doses.   Peak  and overall  plasma  concentrations  were  dose  proportional  over the dosing  
range  of 5mg to 50mg.   Exposure  (AUC)  in multiple  myeloma  patients  is 57% higher  than in 
healthy  male  volunteers.  
 
Pharmacokinetic  Parameters:  
 
Distribution:  
 
In vitro (14C)-lenalidomide  binding  to plasma  proteins  is approximately  30%.  
 
Metabolism  and Excretion:  
 
The metabolic profile of lenalidomide in humans has not been studied. In healthy volunteers, 
approximately  two-thirds  of lenalidomide is eliminated  unchanged  through urinary  excretion.  The 
process  exceeds  the glomerular  filtration  rate and therefore  is partially  or entirely  active.   Half-life 
of elimination  is approximately  3 hours.  
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 5.1.2  Supplier(s)  
 
Celgene  Corporation  will supply  Revlimid®  (lenalidomide)  to study  participants  at no 
charge  through  Celgene’s  Revlimid  Risk Evaluation and Mitigation  Strategy™  (REMS)  
(formerly  known  as RevAssist®  Program).  
5.1.3  Dosage  form  
 
Lenalidomide  will be supplied  as capsules  for oral administration.  
 
5.1.4  Packaging  
 
Lenalidomide  will be shipped  directly  to patients.  Bottles  will contain  a sufficient  number of 
capsules  for one cycle  of dosing . 
 
5.1.5  Storage  
 
Lenalidomide  should  be stored  at room  temperature  away  from direct  sunlight  and protected  from 
excessive  heat and cold. 
 
5.1.6  Pre scribing  Information  
 
Lenalidomide (Revlimid®)  will be provided  to research  subjects  for the duration  of their participation  
in this trial at no charge  to them or their insurance providers.   Lenalidomide  will be provided  in 
accordance  with the Celgene  Corporation’s  Revlimid  REMS®  program.   Per standard  Revlimid  
REMS®  program  requirements,   all physicians  who prescribe  lenalidomide  for research  subjects  
enrolled  into this trial, and all research  subjects  enrolled  into this trial, must be registered  in, and 
must  comply  with, all requirements  of the Revlimid  REMS®  program.  
 
Only enough  lenalidomide  for one cycle  of therapy  will be supplied  to the patient  each  cycle . 
 
 
5.1.7  Pregnancy  Te sting  
Pregnancy  tests  for females  of childbearing  potential.   A female  of childbearing  potential  (FCBP)  
is a sexually  mature  female  who: 1) has not undergone  a hysterectomy  or bilateral  
oophorectomy;  or 2) has not been  naturally  postmenopausal  for at least 24 consecutive  months  
(i.e., has had menses  at any time in the preceding  24 consecutive  months).  
 
Pregnancy  tests  must  occur within  10 – 14 days and again  within  24 hours  prior to prescribing  
lenalidomide  for Cycle  1 (prescriptions  must  be filled within  7 days).   FCBP  with regular  or no 
menstruation  must  have  a pregnancy  test weekly  for the first 28 days  and then every  28 days  
while  on therapy  (including  breaks  in therapy);  at discontinuation  of lenalidomide  and at Day 28 
post the last dose  of lenalidomide.   Females  with irregular  menstruation  must  have  a pregnancy  
test weekly  for the first 28 days  and then every  14 days  while  on therapy  (including  breaks  in 
therapy),  at discontinuation  of lenalidomide  and at Day 14 and Day 28 post the last dose  of 
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 lenalidomide  (see Appendix:  Risks  of Fetal  Exposure,  Pregnancy  Testing  Guidelines  and 
Acceptable  Birth Control  Methods).  
 
5.2 Dexamethasone  
 
 
5.2.1  De scription  
 
Dexamethasone  is a synthetic  adrenocortical  steroid.  Corticosteroids  are naturally -occurring  
chemicals  produced  by the adrenal  glands  located above  the kidneys.  Corticosteroids  affect  the 
function  of many  cells within  the body  and suppress  the immune  system.  Corticosteroids  also 
block  inflammation  and are used  in a wide variety  of inflammatory  diseases  affecting  many  
organs.  
The molecular  weight  for dexamethasone  is 392.47.   It is designated  chemically  as 9-fluoro - 
11β,17,21 -trihydroxy -16α-methylpregna -1,4-diene -3,20-dione.  The empirical  formula  is C22H29FO 5 
and the structural  formula  is: 
 
 
 
 
 
Dexamethasone  is stable  in air and almost  insoluble  in water.  
 
 
5.2.2  Form  
 
Dexamethasone  is a white  to practically  white,  odorless,  crystalline  powder.  It is available  in 2 or 4 
mg tablets  (commercially)  for oral administration.   Each  tablet  contains  dexamethasone  as the 
active  ingredient,  and the following  inactive  ingredients:  calcium  phosphate , lactose , magnesium  
stearate,  and starch.  The tablet  shell may contain  the following:  D&C Yellow  10, FD&C  Yellow  6, 
and/or  FD&C  Blue 1. 
 
5.2.3  Storage  and Stability  
 
All investigational  study  drugs  will be stored  in a locked,  safe area to prevent  unauthorized  
access.  Dexamethasone  should  be stored  at controlled  room temperature,  68-77◦F (20-25◦C) 
and not frozen,  and according  to label requirements.  

Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 5.2.4  Handling 
Dexamethasone  should  be handled  by trained  pharmacy  staff.   The use of gloves  and other  
appropriate  protective  clothing  is recommended  as necessary.  
 
 
5.2.5  Availability  and ordering  
Dexamethasone  supply  will be obtained  through  commercial  supply.   The investigator  will order  
drug supply  from commercial  supply  and will not be provided  for the current  trial. 
 
5.2.6  Preparation  
 
Dexamethasone  is an oral drug,  and does  not require  specific  preparation  details.  
 
 
6.0 CRITERIA  FOR SUBJECT  ELIGIBILITY  
 
6.1 Subject  Inclusion  Criteria  
 
Patients  fulfilling  the following  criteria  will be eligible  for entry  into this study:  
 
  Patients  must  be 18 years  of age or above  at the time of enrollment.  
  Patients  must  show  evidence  of asymptomatic  relapse  and/or  progression  of disease  
(increasing  M spike  in serum  or urine  by consensus  criteria)  while  on lenalidomide  
maintenance  after HDM/ASCT  as part of initial  line of therapy.  Patients  who have  not 
had an HDM/ASCT  as part of initial  line of therapy  but who are on 
continuous/maintenance  lenalidomide  after initial  therapy  will be permitted  on study.  
  Patient  must have  myeloma that is measurable by either  serum  or urine  evaluation  of the 
monoclonal component or by assay of serum free light chains.  Measurable disease is 
defined  as one or more  of the following:  serum  M-protein  > 0.5 g/dl, urine  M-protein  > 
200 mg/24  h, and/or  serum  FLC assay:  involved  FLC level > 10 mg/dL  with abnormal  
serum FLC ratio. 
  Patients  must  have  adequate  organ  function  including:  Hepatic  function  with Bilirubin  < 
2x the upper  limit of normal  and ALT and AST < 3 x the upper  limit of normal;  renal  
function  with creatinine  clearance  > 60 ml/min  using  the Cockcroft -Gault  formula;  
hematologic  function  as defined  by an absolute  neutrophil  count  > 1000  neutrophils  per 
microliter,  platelet  > 50,000  platelets  per microliter  and hemoglobin  of > 9 gm/dL  without  
transfusion  support.  
  All study  participants  must  be registered  into the mandatory  Revlimid  REMS®  program,  
and be willing  and able to comply  with the requirements  of the REMS®  program.  
 Females  of child bearing  potential  (FCBP)1 must  adhere  to the scheduled  pregnancy  
testing  as required  in the Revlimid  REMS®  program.  FCBP  must  have  a negative  serum  
 
 
1 A female  of childbearing  potential  is a sexually  mature  female  who: 1) has not undergone  a hysterectomy  or bilateral  oophorectomy;  or 
2) has not been  naturally  postmenopausal  for at least 24 consecutive  months  (i.e., has had menses  at any time in the preceding  24 
consecutive  months).  
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 or urine  pregnancy  test with a sensitivity  of at least  50 mIU/mL  within  10 – 14 days  and 
again  within  24 hours  prior to prescribing  lenalidomide  for Cycle  1 (prescriptions  must  be 
filled within  7 days)  andmust  either  commit  to continued  abstinence  from heterosexual  
intercourse  or begin  TWO  acceptable  methods  of birth control,  one highly  effective  
method  and one additional  effective  method  AT THE SAME  TIME,  at least  28 days  
before  she starts  taking  lenalidomide.   FCBP  must  also agree  to ongoing  pregnancy  
testing.   Men must agree  to use a latex condom  during  sexual  contact  with a FCBP  even  
if they have  had a successful  vasectomy.   See Appendix:  Risks  of Fetal  Exposure,  
Pregnancy  Testing  Guidelines  and Acceptable  Birth Control  Methods.  
 
6.2 Subject  Exclusion  Criteria  
 
The following  patients  will be ineligible  for registration  onto this study:  
 
  Patients  with symptomatic  relapse  and/or  progression  of multiple  myeloma.  (Appendix  A). 
  Patients  with plasma  cell leukemia.  
  Karnofsky  performance  score  less than 70% or ECOG  performance  status  greater  than 2. 
  Patients  with uncontrolled  bacterial,  viral or fungal  infections  (currently  taking  
medication  and progression  of clinical  symptoms).  
  Patients  with prior malignancies  except  resected  basal  cell carcinoma  or treated  cervical  
carcinoma  in situ or other  cancer  treated  with curative  intent  > 5 years  previously.  
Cancer  treated  with curative  intent  < 5 years  previously  will not be allowed  unless  
approved  by the Protocol  Chairs.  
  Female patients who are pregnant (positive 
-HCG) or breastfeeding. (Lactating 
females  must  agree  not to breast  feed while  taking  lenalidomide).  
  Patients  seropositive  for the human  immunodeficiency  virus (HIV).  
  Prior  organ  transplant  requiring  immunosuppressive therapy.  
  Patients  who were  previously  exposed  to higher  doses  of lenalidomide  and who 
developed  severe  adverse  events  at higher  doses  that preclude  incremental  
dosing.  
 
7.0 RECRUITMENT  PLAN  
 
This study  will be conducted  at MSKCC  and other collaborating  medical  centers  that are 
members  of the newly  established  Tri-State  Transplant  Consortium.  It is anticipated  that 15 
patients  will be enrolled  from MSKCC  and 38 patients  will be enrolled  from the collaborating  
centers.  At MSKCC,  patients  will be recruited  from the large population  of patients  who currently  
undergo  (or have  undergone)  HDM/ASCT  either on the currently  accruing  transplant  clinical  trial 
(IRB # 09-171),  or past clinical  trial (IRB # 05-080),  which  both include   maintenance  therapy   
with lenalidomide  after HDM/ASCT  as part of management;  patients  will also be recruited    
among  patients  who have been  transplanted off protocol  and receive  maintenance  lenalidomide  
after transplantation,  a practice  that has been  gaining  momentum  in the past year.  Patients  who 
have  not had an ASCT  as part of initial  line of therapy  but are on continuous/maintenance  
lenalidomide  will also be permitted  on study.This  trial will also be open  at collaborating  centers  
which  have  agreed  to participate  and we anticipate  that a substantial  proportion  of patients  will 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 be accrued  through  this collaboration.  All patients  will be registered  through  MSKCC.  All  
patients  will be enrolled  and followed  by physicians  at MSKCC  and collaborating  centers.  All co- 
investigators  agree  to follow  the treatment  in the protocol  and to conduct  the proposed  
investigation  according  to recognized  principles  of good  clinical  practice.  Participation  is 
voluntary.  Efforts  will be made  to ensure  that women  and minority  groups  are adequately  
represented  in this trial. Each  patient  must  be informed  about  the neoplastic  nature  of his/her  
disease  and willingly  consent  to participating  in this study.  Every  patient  will be informed  of the 
procedures  to be followed,  the potential  benefits,  side effects,  risks,  and discomforts  of the trial 
and of potential  therapeutic  alternatives.  All participants  will be required  to sign statements  of 
informed  consent  and research  authorization  that conform  to FDA,  IRB and HIPAA  guidelines.  
Informed  consent  will be documented  by the use of a written  consent  form that has been  
approved  by the MSKCC  IRB. 
 
Potential  research  subjects  will be identified  by a member  of the patient’s  treatment  team,  the 
protocol  investigator,  or research  team  at Memorial  Sloan -Kettering  Cancer  Center  (MSKCC).  If 
the investigator  is a member of the treatment  team,  s/he will screen  their patient’s  medical  
records  for suitable  research  study  participants  and discuss  the study  and their potential  for 
enrolling  in the research  study.  Potential  subjects  contacted  by their treating  physician  will be 
referred  to the investigator/research  staff of the study.  
 
The principal  investigator  may also screen  the medical  records  of patients  with whom they  do 
not have  a treatment  relationship  for the limited  purpose  of identifying  patients  who would  be 
eligible  to enroll  in the study  and to record  appropriate  contact  information  in order  to approach  
these  patients  regarding  the possibility  of enrolling  in the study.  This will allow  the study  team to 
keep  track  of all patients  on lenalidomide  maintenance  therapy  for multiple  myeloma  that may 
subsequently  be eligible  to enroll  onto this study.  The study  staff and PI will review  lists from 
Darwin  queries.  The patients  on these  queries  will be tracked  via a log. 
 
During  the initial  conversation  between  the investigator/research  staff and the patient,  the 
patient  may be asked  to provide  certain  health  information  that is necessary  to the recruitment  
and enrollment  process.  The investigator/research staff may also review  portions  of their 
medical  records  at MSKCC  in order  to further  access  eligibility.  They  will use the information  
provided  by the patient  and/or  medical  record  to confirm  that the patient  is eligibile  and to 
contact  the patient  regarding  study  enrollment.  If the patient  turns  out to ineligible  for the 
research  study,  the research  staff will destroy  all information  collected  on the patient  during  the 
initial  conversation  and medical  records  review,  except  for any information  that must  be 
maintained  for screening  log purposes.  
 
In most  cases,  the initial  contact  with the prospective  subject  will be conducted  either  by the 
treatment  team,  investigator  or the research  staff working  in consultation  with the treatment  
team.  The recruitment  process  outlined  presents  no more  than minimal  risk to the privacy  of the 
patients  who are screened  and minimal  PHI will be maintained  as part of a screening  log. For 
these  reasons,  we seek a (partial)  limited  waiver  of authorization  for the purposes  of (1) 
reviewing  medical  records  to identify  potential  research  subjects  and obtain  information relevant  
to the enrollment  process;  (2) conversing  with patients  regarding  possible  enrollment;  (3) 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 handling  of PHI contained  within  those  records  and provided  by the potential  subjects;  and (4) 
maintaining  information  in a screening  log of patients  approached  (if applicable).  
 
This limited  waiver  will apply  only to MSKCC.  Any participating  sites that require  a limited  waiver  
must  obtain  it from their own local IRB/Privacy  Board  (PB) via a separate  protocol  addendum  or 
request.  It is the responsibility  of the MSKCC  staff to confirm  the participating  data collection  
site(s)  have  a limited  waiver  approved  by their local IRB(s)/PBs.  
 
 
8.0 PRETREATMENT  EVALUATION  
 
The following  tests will be done  within  7 da ys prior to enrollment:  
 
  Manda tory pregnancy test, serum or urine HCG (sensitivity of at least  50 mIU/mL) for 
FCBP.  
Women  are required  to have  2 pregnancy  tests prior initiation  of lenalidomide  as follows  
(Appendix B): 
o The first is required  within  10 to 14 days  prior to prescribing  lenalidomide  
o The second  within  24 hours  of prescribing  lenalidomide  and prescription  must be 
filled within  7 days.  
 
The following  tests will be done  within  14 days prior to enrollment:  
 
  History  and physical  exam  including  vital signs,  height,  weight,  performance  status,  and 
toxicity  assessment  using  CTCAE  4.0. 
 
  Serum  M-spike  studies:  Serum  protein  electrophoresis  (SPEP),  serum  immunofixation  (IF) 
and quantitative  immunoglobulins,  and serum  free light chain assay  
 
  Urine  M-spike  studies:  Twenty -four hour urine  for total volume  and total protein  (TV, TP), 
immunofixation  (IF), protein  electrophoresis  (UPEP),  N-telopeptides  and creatinine  
clearance  using  the Cockcroft -Gault  formula  
 
 Comprehensive  Metabolic  Panel  (includes  Albumin,  Alkaline  Phosphatase,  ALT, AST,  
BUN,  Calcium,  Carbon  dioxide,  Chloride,  Creatinine,  Glucose,  Potassium,  Sodium,  Total  
Bilirubin,  Total  Protein),  beta2 -microglobulin,  C-reactive  protein,  LDH 
 
  CBC with differential  
 
  INR/PTT,  BNP,  and troponin.  
 
  Electrocardiogram  (EKG)  
 
  Manda tory pregnancy test, serum or urine HCG (sensitivity of at least  50 mIU/mL) for 
FCBP.  
Women  are required  to have  2 pregnancy  tests prior initiation  of lenalidomide  as follows  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 (Appendix B): 
o The first is required  within  10 to 14 days prior to prescribing  lenalidomide  
o The second  within  24 hours  of prescribing  lenalidomide  and prescription  must be 
filled within  7 days.  
 
The following  tests will be performed  within  56 days prior to patient  enrollment:  
  Hepatitis  A, B, C serologies  and HIV l/2 test 
 
  A skeletal  survey  that should  be reviewed  at MSKCC  or the participating  site if not 
performed  at MSKCC  or the participating  site. (Please  note:  the skeletal  survey  is not 
required  if a PET scan has been  completed)  
 
  PET scan  or total body  MRI if available  (optional)  
 
  A routine  bone  marrow  examination,  including  biopsy  sample  for H & E stain  and 
immunohistochemical  staining  for CD 138, CD20,  kappa  and lambda  light chains;  bone 
marrow  aspirate  samples  for Giemsa  staining,  flow-cytometry,  cytogenetic  analysis,  and 
FISH  analysis  for chromosomes  1,  4, 11, 13, 14, 17 abnormalities  
 
 
9.0 TREATMENT/INTERVENTION  PLAN 
9.1 Treatment  Plan  
 
Lenalidomide  dose  will begin  at 25 mg PO daily for 21 days of a 28-day-cycle  adjusted  
for toxicity,  if necessary.   Once  the dose  of lenalidomide  is reduced  for toxicity,  no dose - 
re- escalation  is permitted.  
 
If a dose  of lenalidomide  is missed,  it should  be taken  as soon  as possible  on the 
same  day.  If it is missed  for the entire  day, it should  not be made  up. 
 
Patients  taking  more  than the prescribed  dose  of lenalidomide  should  be instructed  to 
seek  emergency  medical  care if needed  and contact  study  staff immediately.  
 
Only one cycle  of therapy  may be dispensed  to the patient  each  month.  
Lenalidomide  capsules  should  be swallowed  whole,  and should  not be broken,  
chewed  or opened.  
 
Special  Handling  Instructions:   Females  of childbearing  potential  should  not handle  
or administer  lenalidomide unless  they are wearing gloves.  
 
Record  of administration:   Accurate  records  will be kept in the source  documents  of all 
drug administration  (including prescribing  and dosing).  Patients  will be instructed  to bring  
their complete  medication  diary  (refer  to Appendix  D) to each  study  visit for assessment  of 
compliance.  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
  
Patient  will be evaluated  for response  and toxicity  after every  cycle  and the response  
to lenalidomide  intensification  will be assessed  after every  cycle  of therapy.  
 
o Patients  with at least SD after 2 cycles  of lenalidomide  will continue  on 
lenalidomide  until asymptomatic  POD at which time dexamethasone  will be 
added  at a dose  of 40 mg PO weekly  for the next cycle.  
 
o Patients  with asymptomatic  POD  after 2 cycles  of lenalidomide  will have  
dexamethasone  added  to lenalidomide  at a dose  of 40 mg PO weekly  with the 
next cycle.  
 
o Patients  with further  asymptomatic  POD  after any cycle  of lenalidomide  and 
dexamethasone  will be taken  off study  and treated  at the discretion  of the 
treating  physician.  Note that further  POD  after the addition  of dexamethasone  
will be determined  compared  to the new M spike  baseline  just prior to the 
addition  of dexamethasone.  
 
Once  patients  are started  on dexamethasone,  they will also receive  prophylaxis  
medication  including  Bactrim DS,  one tablet  PO TIW, fluconazole,  100 mg PO Daily,  ASA 
81 mg PO daily,  and a PPI. 
 
Note that patients  with symptomatic  POD  at any point  in time during  treatment  will 
be taken  off study.  
 
 
9.2 Cycle  Delay  and Dose  Modification  Guidelines  
 
Within  a week  prior to the first day of each  new treatment  cycle,  the patient  will be evaluated  for 
possible  toxicities  that may have  occurred  due to previous  doses.  Toxicities  will be assessed  
according  to the National  Cancer  Institute  Common Terminology  Criteria  for Adverse  Events  (NCI 
CTCAE),  version  4.0. Cycle  delays  and dose  modifications  will be made  based  on the toxicity  
experienced  during  the previous  cycle of therapy  or the ones  encountered  on any of the treatment  
days.  Doses  of study  drug that need  to be held WITHIN  a cycle  are skipped  and will not be made  
up later in the cycle.  
 
9.2.1.  Instruction  for Initiation  of a New Cycle  
 
A new course  of treatment  may begin  on the scheduled  Day 1 of a new cycle  if: 
 
The ANC is ≥ 1,000/μL 
The platelet  count  is ≥ 50,000/μL  
Hemoglobin  is ≥ 8g/dL  
Any drug-related  side effect  rash,  allergic  reaction/hypersensitivity,  sinus  bradycardia/  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 other  cardiac  arrhythmia adverse  event,  dyspepsia,  gastritis,  gastric  or duodenal  ulcer  or 
confusion  or mood  alterations  that may have  occurred  has resolved  to ≤ grade  1 severity  
Any other  drug-related  adverse  events  that may have  occurred  have  resolved  to ≤ grade  2 
severity.  
 
If these  conditions  are not met on Day 1 of a new cycle,  the subject  will be evaluated  weekly  and a 
new cycle  of lenalidomide  will not be initiated  until the toxicity  has resolved  as described  above.  If 
the toxicity  does  not resolve  after four weeks  of delay,  the patient  will be taken  off study.  
 
If dosing  of lenalidomide  was halted  during  the previous  cycle  and was restarted  with a one-level 
dose  reduction  without  requiring  an interruption  for the remainder  of the cycle,  then that reduced  
dose  level will be initiated  on Day 1 of the new cycle.  
 
If dosing  of lenalidomide  was omitted  for the remainder  of the previous  cycle  or if the new cycle  is 
delayed  due to toxicity  newly  encountered  on the scheduled  Day 1, then the new cycle  will be 
started  with dose  modifications  as described  in Section  9.2.3.  
 
9.2.2.  Lenalidomide Dose Reduction Guidelines 
 
Table 3: Dose Modification for Lenalidomide 
NCI CTC v 3.0 Toxicity  
Grade  Day 2 – 14 of Cycle  ≥ Day 15 of Cycle  
Grade  3 neutropenia  
associated  with fever  
(temperature  ≥ 38.5oC or 
Grade  4 neutropenia)  
   Hold (interrupt  dose)  
   Follow  CBC weekly  
   If neutropenia  has resolved  
to ≤ grade  2 prior to Day 21, 
restart  at next lower  dose  
level and continue  the cycle  
until Day 21. 
   Omit lenalidomide  for 
remainder  of the cycle  
   If neutropenia  is the only 
toxicity  for which  a dose  
reduction  is required,  G-CSF 
may be used  and the dose 
maintained  for the next cycle  
at the treating physician’s  
discretion  
Thrombocytopenia  ≥ 
Grade  3 (platelet  count  < 
50,000/mm3) 
   Hold (interrupt  dose)  
   Follow  CBC weekly  
   If thrombocytopenia  
resolves  to ≤ grade  2 prior 
to Day 21, restart  at next 
lower  dose  level and 
continue  the cycle  until Day 
21 
   Hold anticoagulation  for 
platelet  count  < 50,000/mm3 
   Omit lenalidomide  for 
remainder of cycle  
   Hold anticoagulation  for 
platelet  count  < 50,000/mm3 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 Anemia  ≥ Grade  3 (Hgb  
< 8g/dL  
   Hold (interrupt  dose)  
   Follow  CBC weekly  
   If anemia  resolves  to ≤ 
grade  2 prior to Day 21, 
restart  at next lower  dose  
level and continue  the cycle  
until Day 21 
   Omit lenalidomide  for 
remainder of cycle  
Non-blistering  rash 
Grade  3 
   Hold (interrupt  dose)  
   Follow  weekly  
   Omit lenalidomide  for 
remainder of cycle  
 
    If the toxicity  resolves  to ≤ 
grade  1 prior to Day 21, 
restart  at next lower  dose  
level and continue  the cycle  
until Day 21  
Non-blistering  rash 
Grade  4 
   Discontinue  lenalidomide  
study  drug 
   Discontinue  lenalidomide  
study  drug 
Desquamating  
(blistering)  rash - any 
Grade  
   Discontinue  lenalidomide  
study  drug 
   Discontinue  lenalidomide  
study  drug 
Erythema multiforme  ≥ 
Grade  3 
   Discontinue  lenalidomide  
study  drug 
   Discontinue  lenalidomide  
study  drug 
Sinus  bradycardia/other  
cardiac  arrhythmia  Grade  
2 
   Hold (interrupt)  dose  
 Follow  at least weekly  
   If toxicity  resolves  to ≤ 
grade  1 prior to Day 21, 
restart  at next lower  dose  
level and continue  the cycle  
until Day 21 
   Omit lenalidomide  for 
remainder of cycle  
Sinus  bradycardia/other  
cardiac  arrhythmia  ≥ 
Grade  3 
   Discontinue  lenalidomide  
study  drug 
   Discontinue  lenalidomide  
study  drug 
Allergic  reaction or 
hypersensitivity  Grade  2- 
3 
   Hold (interrupt)  dose  
   Follow  at least weekly  
   If toxicity  resolves  to ≤ 
grade  1 prior to Day 21, 
restart  at next lower  dose  
level and continue  the cycle  
until Day 21 
   Omit lenalidomide  for 
remainder of cycle  
Allergic  reaction or 
hypersensitivity  Grade  4 
   Discontinue  lenalidomide  
study  drug 
   Discontinue  lenalidomide  
study  drug 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 Venous  
thrombosis/embolism  ≥ 
Grade  3 
   Hold (interrupt  dose)  and 
start anticoagulation;  restart  
at investigator’s  discretion  
(maintain  dose  level)  
   Omit lenalidomide  for 
remainder of cycle  
Other  non-hematologic  
toxicity  assessed  as 
Lenalidomide -related  ≥ 
Grade  3 
   Hold (interrupt  dose)  
   Follow  at least weekly  
   If toxicity  resolves  to ≤ 
grade  1 prior to Day 21, 
restart  at next lower  dose  
level and continue  the cycle  
until Day 21 
   Omit lenalidomide  for 
remainder of cycle  
Hyperthyroidism  or 
hypothyroidism  
   Omit lenalidomide  for 
remainder  of cycle,  evaluation  
etiology,  and initiate  
appropriate  therapy  
   See Instructions  for  
Initiation  of a New Cycle  
and reduce  the dose  of 
lenalidomide  by 1 dose  level 
   Omit lenalidomide  for 
remainder of cycle,  
evaluation  etiology,  and 
initiate appropriate  therapy  
   See Instructions  for Initiation  
of a New Cycle  and reduce  
the dose  of lenalidomide  by 
1 dose  level 
 
 
9.2.3.  Le nalidomide Dose Reduction Levels 
 
 
Lenalidomide  Dose  Reduction  Steps  
Starting  Dose  25 mg daily for 21 days every  28 days 
Dose  Level  -1 20 mg daily for 21 days every  28 days 
Dose  Level  -2 15 mg daily for 21 days every  28 days 
Dose  Level  -3 10 mg daily for 21 days every  28 days 
Dose  level -4 5 mg daily for 21 days every  28 days  
Dose  level -5 Discontinue  lenalidomide  
 
 
9.2.4  Dexame  thasone  Dose  Reduction  Guidelines  
 
Table  4: Dose  Modification  for Dexamethasone  
Dyspepsia  ≥ Grade  3 
  Hold (interrupt)  
dexamethasone  until ≤ 
grade  1 
  Reduce  dexamethasone  by 1 
dose  level and restart  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 Gastritis,  
gastric  or duodenal  ulcer  ≥ Grade  3 
  Hold (interrupt)  
dexamethasone  until ≤ 
grade  1 
  Reduce  dexamethasone  by 1 
dose  level and restart  
Edema  ≥ Grade  3 
   Reduce dexamethasone  by 1 dose  
level 
  Use diuretics,  as needed  
Confusion  or mood  
alternations  ≥ Grade  2 
  Hold (interrupt)  
dexamethasone  until ≤ 
grade  1 
  Reduce  dexamethasone  by 1 
Muscle  weakness  ≥ Grade  3 
   Reduce dexamethasone  by 1 dose  
  
   If symptoms  persist,  continue  to 
reduce  dexamethasone  by 1 dose  
level,  as needed  
Hyperglycemia  ≥ Grade  3 
   Reduce dexamethasone  by 1 dose  
level 
  Treat  with insulin  or oral 
hypoglycemics,  as needed  
Acute  pancreatitis  ≥ Grade  3 
   Discontinue  dexamethasone  
and take patient  off study  
Other  non-hematologic  
toxicity  assessed  as 
dexamethasone  related  ≥ Grade  3 
   Hold dexamethasone  for 
remainder  of cycle  
 Reduce  dexamethasone  by 1 
dose  level 
 
9.2.5  Dexame  thasone  dose  reduction  levels  
 
 
Dexame thasone Dose Reduction Ste ps 
 
Starting  Dose   
40mg  weekly  on days 1, 8, 15 and 22 of each  28-day 
cycle  
 
Dose  Level  -1  
20mg  weekly  on days 1, 8, 15 and 22 of each  28-day 
cycle  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
  
Dose  Level  –2  
12mg  weekly  on days 1, 8, 15 and 22 of each  28-day 
cycle  
 
Dose  Level  -3  
4mg weekly  on days  1, 8, 15 and 22 of each  28-day 
cycle  
 
9.3 Supportive  Care  
 
• Monthly  IV bisphosphonates  (either Zometa  or Pamidronate according  to 
institutional  preference)  may be initiated  or continued  according  to local institutional  
practice.  
• Patients  can receive  filgrastim  or pegylated  filgrastim  for an ANC < 109/L.  
• Radiation  therapy  is not permitted  concurrently  in this trial. 
• Transfusion  thresholds  for blood  product  support  should  be per institutional  
guidelines.   All blood  products  will be irradiated.  
• Treating  physicians  should  be aware  of the increased  risk of DVT and PE with 
lenalidomide  when  combined  with dexamethasone  and have  heightened  vigilance  
regarding  this possible  toxicity.  There  is no clear  evidence  that the risk of DVT is 
increased  on lenalidomide alone.  Aspirin 325 mg/day  orally  should  be administered  
during  lenalidomide  therapy  when associated  with dexamethasone  unless  the 
patient  is treated  with alternate  prophylaxis  of either  low molecular  weight  heparin  
or Coumadin.  This will be left to the discretion  of the treating  physician.  
• Concurrent  use of erythropoietin  requires  full anticoagulation  of patients  with 
therapeutic  doses  of LMWH  or Coumadin.  Anticoagulation  should  be held for 
platelet  counts <50,000/mm3.  
• Prophylaxis  therapy  should  be added  when patient  start dexamethasone  including  
fluconazole  100mg  PO daily,  Bactrim DS,  three  days a week,  and a PPI daily.  
 
 
10.1 EVALUATION  DURING  TREATMENT/INTERVENTION  
 
During  the intervention  period,  the patients  will be assessed  in the clinic  before  initiation  of 
every  cycle  and will have  the following  evaluation  done  before  every  cycle,  within  one 
week  of day 1 of the cycle:  
 
• History  and physical  exam  including  vital signs,  weight,  and performance  status.  
• Review  medication  diary.  Patients  will be given  a medication  diary  at the beginning  
of each  cycle  to  document  lenalidomide  administration.  
• CBC with differential  and platelet  count  
• Comprehensive  metabolic  panel  with LDH and phosphorus.  The comprehensive  
metabolic  panel  includes  albumin,  alkaline  phosphatase,  ALT, AST,  BUN,  calcium,  
carbon  dioxide,  chloride,  creatinine,  glucose,  potassium,  sodium,  total bilirubin,  and 
total protein.  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 • Myeloma  response  assessment:  Including  serum studies  (Protein  electrophoresis,  
Quantitative  Immunoglobulins,  Immunofixation  and free light chain  assay)  and 24h 
urine  studies  (protein  electrophoresis,  Total  protein,  Immunofixation,  and creatinine  
clearance)  
• Toxicity  assessment  using  CTCAE  4.0: maximum  grade  and status  of ≥ grade  2 
adverse  events.  
• Bone  marrow  aspiration  and biopsy  to be performed  only when  indicated  to 
document  CR or progression.  
• Radiological  evaluation  when  needed  to document  response or progression.  
• Required  evaluation  for Lenalidomide:  Pregnancy  test, serum  or urine  HCG  
(sensitivity  of at least 50 mIU/mL)  for female  of childbearing  potential  (FCBP):  
• FCBP  with regular  or no menstruation  must  have  a pregnancy  test weekly  for the 
first 28 days and then every  28 days  while  on therapy  (including  breaks  in therapy);  
at discontinuation  of lenalidomide  and at Day 28 post the last dose  of lenalidomide.  
Females  with irregular  menstruation  must  have  a pregnancy  test weekly  for the first 
28 days and then every  14 days while  on therapy  (including  breaks  in therapy),  at 
discontinuation  of lenalidomide  and at Day 14 and Day 28 post the last dose  of 
lenalidomide  (Appendix  B). 
• All patients  must  be counseled  about  pregnancy  precautions,  risks of fetal exposure  
and other  risks.  The counseling  must  be done  on Day 1 of each  cycle  (or at a 
minimum of every  28 days)  and at drug discontinuation.  See Appendix:  Education  
and Counseling  Guidance  Document.  A Lenalidomide  Information  Sheet  (Appendix  
D) will be supplied  with each  medication  dispense.  
 
The same  evaluation  will repeated  at the end of study,  within  4 weeks  of the last dose.  On 
day 15 of each  cycle  the patient  will have  a CBC.  Pre-screening  assessments  may be used  
for Cycle  1/Day  1 if they were  complete  within  7 days  of initiation  of cycle  1. 
 
 
Correlative Studies 
Patients  who give their consent  to optional  sample  collection  for research  studies  will have  
blood  samples  (6 CPT tubes  and 1 SST tube)  collected  for research  on immune  function  
prior to lenalidomide  dose  escalation,  Cycle  1, Day 15 (+/- 3 days)   following  dose  
escalation,  prior to addition  of dexamethasone,  and Day 15 (+/- 3 days)   following  the 
addition  of dexamethasone.   Research  blood  samples  will be collected  during  the time of 
standard  toxicity  evaluation  during  lenalidomide  therapy.   The standard  treatment  schedule  
includes  a 7 day rest period  prior to the administration  of the next cycle.  Thus,  the day 15 
time point  has been  selected  to allow  for an analysis  of immune  endpoints  during  the period  
when  study  drug is being  administered.  In addition,  5-7 cc of bone  marrow  aspirate  (in 
EDTA)  will be collected  at the time of registration.   Samples  will be sent to MSKCC  for 
central  processing,  cataloguing,  and storage.  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
  
 
Time  Point  Window  for 
Collection  Tubes  
Baseline/pre - 
lenalidomide  
escalation  Day -7(consent  must  
be signed)  through  
Cycle  1/Day  1 5-7cc bone  
marrow aspirate  
(6) CPT tubes  
(1) SST tube 
Cycle  1/Day  15 Cycle  1/ Day 15 (+/- 3 
days)  (6) CPT tubes  
(1) SST tube 
Pre-dexamethasone  
addition  Between  
asymptomatic  
progression  and 
addition  of 
dexamethasone  (6) CPT tubes  
(1) SST tube 
Day 15 post- 
dexamethasone  
addition  Day 15 (+/- 3 days)  
post-dexamethasone  
addition  (6) CPT tubes  
(1) SST tube 
 
 
Schedule of Study Assess ments 
 
 
Required  Studies  / Testing   
Pretreatment  
w ithin  8 weeks  Pretreatme  
nt w ithin 28 
days  Pretreatment  
w ithin  14 
days  Before   Every 
Cycle  (within  
1 week  of 
day 1) 8 On day 15 
of each 
cycle  End o 
Stud  
(Within  
weeks  of 
dose) 
Infor med Consent   X     
History  and Physical  Examination 
(Height  7  and Weight)    X X  X 
Vital Signs    X X  X 
Rev iew medication  diary     X  X 
Toxicity  assessment    X X  X 
Pr egnancy  Test2
   X3 X3  X3 
Register  patient  into the Rev limid 
REMS™  program    X    
Perf ormance  Status  (Karnofsky  
Performance  Score  or ECOG)    X X  X 
CBC  w ith Differential  and platelet  
count    X X X X 
Comprehensive  Metabolic  Panel  6   X X  X 
LDH,  Phosphorus    X X  X 
B2 Microglobulin,  Albumin    X X  X 
INR/ PTT,  BNP,  troponin    X    
Hepat  itis A, B, and C and HIV 1/2 
test X      
Serum  Multiple  Myeloma  Disease  
Assessment  
 Protein  electrophoresis  
 Quantitative     
 
X  
 
X   
 
X 
 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 To be perf or med w ithin 8 w eeks of registration.  
2 Pregnancy tests  for females  of childbearing  potential:  A female  of childbearing  potent  ial (FCBP) is a sexually  
mature  female w ho: 1) has not  undergone  a hysterectomy  or bilateral  oophorectomy;  or 2) has not been  
naturally  postmenopausal  for at least  24 consecutive  months  (i.e., has had menses  at any time in the 
preceding  24 consecutive  months).  
3 Pregnancy tests  must  occur  w ithin 10 – 14 days  and again  w ithin 24 hours  prior to prescribing  lenalidomide  for 
Cycle  1 (pr escriptions  must  be f illed w ithin 7 days).  FCBP  w ith regular  or no menstruat  ion must  have  a pr egnancy  
test w eekly  for the f irst 28 days  and then every  28 days  w hile on ther apy (including  breaks  in ther apy);  at 
discontinuat  ion of lenalidomide  and at Day 28 post the last dose  of lenalidomide.  Females  w ith irregular  
menstruat  ion mus t have  a pregnancy  test w eekly  for the f irst 28 days  and then every  14 days  w hile on therapy  
(including  breaks  in therapy),  at discont  inuation  of lenalidomide  and at Day 14 and Day 28 post the last dose  of 
lenalidomide  (see Appendix: Ris ks of Fetal  Exposure, Pregnancy Testing  Guidelines  and Acceptable  Birth Control  
Methods)  
4 Unilateral  bone  marrow  aspirate  and biopsy  w ill be done  on ly to conf ir m complet  e remission  in patients  w ith negative  
biochemical  evidence  of disease.  
5 If the baseline  urine  paraprotein  level  is less than 200mg/24hrs,  the UPEP  is not required.  
6 Albumin,  Alkaline  Phosphatase, ALT,  AST,  BUN,  Calc ium, Carbon  dioxide,  Chloride,  Creat  inine,  Glucose,  Potassium, 
Sodium,  Total  Bilirubin, Total  Prot ein 
7 Height  only required  during  pretreat  ment  evaluation.  
8 Pre-screening assessments  may be used  f or Cycle  1/ Day 1 if they w ere complet  e w ithin 7 days of initiation  of cycle  1. 
9 Optional  blood  w ill be collected  prior to dose  escalat  ion (baseline),  15 days  (+/- 3 days)  post dose  escalation,  prior  to 
addit  ion of dexamethasone,  and 15 days  (+/- 3 days)post  addition  of dexamethasone.  
10A skeletal  survey  is only required  f or screening  if PET scan  w as not completed.  
 
11.0  TOXICITIES/SIDE  EFFECTS  
 
The patients  will be evaluated  every  28 days  before  initiation  of a new 
cycle  of treatment.  All toxicities  with a maximum  grade  and status  of ≥ 
grade  2 will be graded  using  the Common  Terminology  Criteria  for Immunoglobulins  
 Immunof  ixation  
 Serum  Free Light  Chain  
Assay        
24 hour  Urine  Multiple  My eloma  
Disease  assessment  
 Protein  electrophoresis  
 Immunof  ixation  
 Total  volume,  total  protein  
 Creatinine  clear  ance  
    
 
 
X  
 
X5   
 
 
X 
EKG    X    
Skelet  al Survey  X1,10     X 
PET scan  or total body  MRI if 
available  (opt ional)  X1      
Bone  Marrow  Aspirate  and Biopsy  for 
   Mor phology  
   Cytogenet  ics and FISH  
analysis  
  Tissue  Banking   
X1      
X4 
Opt ional  Research  Blood9
  X     
Opt ional  Research  Bone  Marrow  
Aspirate  X      
 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 Adverse  Events  (CTCAE)  Version  4.0. 
 
11.1 Expected  Side  Effects  of Lenalidomide  
 
Most  frequently  reported  adverse  events  reported  during  clinical  studies  with lenalidomide  
in oncologic  and non-oncologic  indications,  regardless  of presumed  relationship  to study  
medication  include  the following:  
 
Likely: 
  Feeling  tired (fatigue)    Loss  of strength  (asthenia)    Loose,  frequent  bowel  movements  (diarrhea)    Difficulty  moving  bowels  (constipation)    Altered  sense  of taste   (dysgeusia)  
  Nose  bleed  (epistaxis)    Decrease  in red blood  cells that can cause  tiredness  (anemia)    Decrease  in white  blood  cells that can make  you more  prone  to infections  (neutropenia)  
  Decrease  in platelets  which  can cause  you to bruise  or bleed  easily(thrombocytopenia)    Blurred  vision    Abnormal  sense  of touch    Pain and decreased  sensastion  in nerves  
 
Le ss Like ly: 
  Fever    Problem with moving food through digestive system (gastrointestinal  motility  disorder)    Weight  loss, loss of appetite    Dry mouth   Nausea 
  Vomiting    Chills    Indigestion  (dyspepsia)    Muscular  weakness  
  Stroke    Tingling  sensation  (paresthesia)    Swelling  or edema  (including peripheral)  
  Itching  and dry skin (pruritis)    Rash    Sores  on the skin (pyoderma  gangrenosum)    Cough  
  Shortness  of breath  (dyspnea)    Fainting  (syncope)    Dizziness    Drowsiness  
  Heada che   Difficulty  sleeping  (insomnia)    Bleeding    Difficulty  breathing  (respiratory  distress)  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
   Excessive  sweating  (hyperhidrosis)  
  Fever  with a decrease  in white  blood  cells that help fight infections  (febrile  neutropenia)    Shortage  of all types  of blood  cells including  red blood  cells,  white  blood  cells,  and 
platelets  (pancytopenia)    Infection,  especially  when  white  blood  cell count  is low 
  Blood  clots (thromboembolic  event)    Excessive  loss of body  water  (dehydration)    High blood  sugar  (hyperglycemia)    Uncontrolled  blood  sugar  (diabetes  mellitus)  
  Higher  than normal  blood  uric acid (hyperuricemia)    Higher  than normal  level of iron in body  (iron overload)    Lower  than normal  level of thyroid  hormone  (hypothyroidism)  
  Lens  of eye becomes  cloudy  (cataracts)    High blood  pressure  (hypertension)    Low blood  pressure  (hypotension)    Joint pain (arthralgia)  
  Back  pain   Muscle  pain (myalgia)    Muscle  cramp  / spasm    Altered  mood  
  Depression   Irregular  heartbeat  (atrial  fibrillation)    Failure  of the heart  (cardiac  failure)    Heart  attack  (acute  myocardial  infarction)  
  Fast heartbeat  (tachycardia)    Not enough  blood  flow to heart  muscle  (myocardial  ischemia)    Kidney  damage  (renal  failure)    Abnormal  liver function tests  
 
Rare  but Serious  
  Fever  with a decrease  in white  blood  cells that help fight infections  (Febrile  
neutropenia)    Blood  clot in or around  the lungs  (Pulmonary  embolism)    Deep  vein thrombosis  or blood  clots in larger  blood  vessels    Atrial  fibrillation  or irregular  heartbeat  
  Pneumonia  or an infection  of the lungs    Sepsis  or an infection  of the blood  
  Inflammation  of the pancreas,  which  causes  increase  in pancreatic  enzymes  (lipase),  
which  could  result  in abdominal  pain and discomfort    Allergic  reaction  which  may cause  rash,  low blood  pressure,  wheezing,  shortness  of 
breath,  swelling  of the face or throat  (anaphylaxis)    Kidney  failure  or inability  of the kidneys  to remove  waste  from the body    Muscle  breakdown  (rhabdomyoiysis)  
  Swelling  of the lungs    Severe  skin rash with blisters  that can involve  the inside  of the mouth  and other  parts  of 
the body  (erythema  multiforme)    Serious  allergic  skin reactions  that begin  as a rash in one area and later cover  more of 
the body,  leading  to separation  of the top layer of skin (Stevens - Johnson  syndrome  / 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 toxic epidermal  necrolysis)    Damage  to organs  in the body  when  donor  cells attack  host organs,  which  may cause  
yellowing  of the eyes  and skin, itchy dry skin, or muscle  weakness  (Graft  versus  host 
disease)    Complications  caused  by the break -down  products  of dying  cancer  cells,  which  can 
include  high potassium,  high phosphorous,  high uric acid in the blood  and urine,  low 
calcium,  and can result  in kidney  damage  (Tumor  lysis syndrome)    Cancer  of bone  marrow  caused  by chemotherapy    A new cancer  resulting  from treatment  of earlier  cancer  
  Low blood  cell counts  that may cause  infection,  anemia,  spontaneous  bleeding,  or easy 
bruising  (Myelodysplastic  syndrome)    Increase  in size of the cancerous  lymph  nodes,  rash,  and slight  fever  (Tumor  flare 
reaction)    Brain  damage  which  may cause  headache,  seizure,  or blindness  
(leukoencephalopathy)  
11.2 Expected  Side  Effects  of Dexamethasone  
 
Likely  
 
  Increased  appetite  
  Weight  gain 
  Sleep  disturbance  
  Hypertension 
  Fluid  retention,  ankle  swelling  
  Bruising  
  Susceptibility  to Infection  
  Mood  changes  
  Slow  wound  healing  
  Depression  
  Hyperglycemia,  which  may lead to fatigue,  weight  loss, excessive  thirst  and frequent  
urination.  
Le ss Likely  
 
  Loss  of appetite  
  Muscle  twitching  
  Increased  thirst,  frequent  urination  
  Increased  perspiration  
  Diarrhea  
  Nausea  
  Heada che 
  Bone  thinning  
  Spinal  fracture  or fracture  of bones  
  Tachycardia  
  Fungal  infections  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 
  Anxiety  
 
Unlikely  
  Blurred  vision  
  Personality  changes  
  Hypokalemia  
  Swelling  and/or  redness  of skin 
  Allergic  skin reactions  
  Itching  
  Hirsutism  
  Muscle  weakness  or loss of muscle  mass  
  Rupture  of tendons  
  Menstrual  cycle  disturbances  
  Facial  puffiness,  leading  to the appearance  of a “moon  face”  hormonal  disturbances  
  Hiccups.  
  Development  of diabetes  
 
Rare  but serious  
 
  Stomach  ulcers  with bleeding  that may cause  hematemesis,  blood  in the stool and 
abdominal  pain.  
  Bowel  perforation,  irritation  and bleeding  of the esophagus  
  Heart  failure  
  Allergic  reaction  that may lead to shortness  of breath,  abdominal  cramps  and hypotension  
  Convulsions,  brain  swelling,  
  Cataracts  
  Glaucoma  and increased  blood  pressure  in the eye 
  Pancreatic  inflammation,  abdominal  swelling  
  DVT or PE 
  Aseptic  necrosis  of the hip 
 
 
12.0 CRITERIA  FOR THERAPEUTIC  RESPONSE/OUTCOME  
ASSESSMENT  
Patients  enrolled  in this trial must have  asymptomatic  progression  of disease  only. The new 
baseline  that will be used  for comparison  to assess  the response  to lenalidomide  intensification  
with or without  the addition  of dexamethasone  at 6 months  will have  to be established  within  
two weeks  prior to day 1 of cycle  1. Prior values  will not be acceptable.  
Patients’  disease  status  at each  data collection  period  will be evaluated  based  on the International  
Uniform Response  Criteria.   All disease  responses,  including after addition  of dexamethasone,  
will be relative  to the established  baseline  disease  status  within  2 weeks  prior to day1  of cycle  1, 
i.e. prior to lenalidomide  intensification.  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 International Uniform Response Criteria (modified) 
Stringent  Complete  Response  (sCR):  
  sCR requires,  in addition  to CR (defined  below),  all of the following:  
  Normal  free light chain  ratio (FLC).  
  Absence  of clonal  cells in bone  marrow  by immunohistochemistry  or immunofluorescence.  
 
 
Complete  Response  (CR) requires  all of the following:  
 
 Absence  of the original  monoclonal  paraprotein  in serum  and urine  by routine  
electrophoresis  and by immunofixation.  
 Less  than 5% plasma  cells in a bone  marrow  aspirate  and also on trephine  bone  biopsy,  if 
biopsy  is performed;  
 No increase  in size or number  of lytic bone  lesions  on radiological  investigations  
(development  of a compression  fracture  does  not exclude  CR)*;  and, 
  Disappearance  of soft tissue  plasmacytomas.  
 
 
*If not clinically  indicated,  radiographs  are not required  to document  CR. 
 
 
Very  Good  Partial  Response  (VGPR)  requires,  in addition  to PR (defined  below),  all of the 
following:  
 
  Serum  or urine  paraprotein  detectable  by immunofixation  but not on electrophoresis,  
OR 
 Greater  than or equal  to 90% reduction  in serum  paraprotein  plus urine  paraprotein  <100  
mg/24hrs. 
 
Partial  Response  (PR) requires  one of the following:  
 
 Greater  than or equal  to 50% reduction  in the level of the serum  monoclonal  paraprotein  
and/or  reduction  in 24 hour urinary  monoclonal  paraprotein  either  by greater  than or equal  
to 90% or to <200  mg/24  hours  in light chain  disease.  
 If the only measurable  non-bone  marrow  parameter  is FLC,  greater  than or equal  to 50% 
reduction  in the difference  between  involved  and uninvolved  FLC levels  or a 50% 
decrease  in level of involved  FLC with 50% decrease  in ratio,  
 If the bone  marrow  is the only measurable  parameter,  greater  than or equal  to 50% 
reduction  in bone  marrow  plasma  cells given  that the baseline  count  was greater  or equal  
to 30%,  
 Greater than or equal  to 50% reduction  in the size of soft tissue  plasmacytomas  (by 
radiography  or clinical  examination).  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 Minor Response (MR) 
 
 ≥ 25% to ≤ 49% reduction  in the level of serum  monoclonal  protein  (SPEP)  
  If present,  a 50% to 89% reduction  in 24-hour light chain  excretion,  which  still exceeds  
200 mg/24  hr. 
  If the serum  and urine  M-protein  are unmeasurable  a ≥25%  to ≤49% decrease  in the 
difference  between  involved  and uninvolved  FLC levels  is required  in place   of the M- 
protein  criteria.  
  25% to 49 % reduction  in the size of soft tissue  plasmacytomas  (by clinical  or radiographic  
examination)  
 
 
Stable Disease (SD) 
  Patients  who do not meet  criteria  for  sCR,  CR, VGPR,  PR or progressive  disease  are 
considered  to have  stable  disease  (SD).  
 
 
Progressive  Disease  (POD)  requires  one or more  of the following:  
 
  >25%  increase  in the level of the serum  monoclonal  paraprotein,  which  must  also be an 
absolute  increase  of at least 0.5 g/dL.  
  >25%  increase  in 24-hour urine  protein  electrophoresis,  which  must  also be an absolute  
increase  of at least 200 mg/24  hours.  
 
  >25%  increase  in the difference  between  involved  and uninvolved  FLC levels    (absolute  
increase  must be >10 mg/dl),  
  >25%  increase  in plasma  cells in a bone  marrow  aspirate  or on trephine  biopsy,  which  
must  also be an absolute  increase  of at least 10%.  
  Definite  increase  in the size of existing  bone  lesions  or soft tissue  plasmacytomas.  
  Development  of new bone  lesions  or soft tissue  plasmacytomas.  
  Development  of hypercalcemia  (corrected  serum  Ca >11.5  mg/dL  or  >2.8 mmol/L)  not 
attributable  to any other  cause.  
Note that the development  of a compression  fracture  does  not exclude  continued  response  
and may not indicate  progression.  
 
 
13.0  CRITERIA  FOR REMOVAL  FROM  STUDY  
 
Treatment  with study  drugs  is to be discontinued  when  any of the following  occurs:  
 
  Symptomatic  POD,  i.e. with organ  damage  at any point  in time during  the treatment  
  Asymptomatic  POD,  i.e. without  organ  damage  after at least one cycle  of lenalidomide  
and dexamethasone  
  Adverse  event(s)  that, in the judgment  of an Investigator,  may cause  severe  or permanent  
harm  or which rule out continuation  of study  drug 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 
  Major  violation  of the study  protocol  
  Withdrawal  of consent  
  Patient  is lost to follow -up 
  Suspected  or confirmed  pregnancy.  If pregnancy  or a positive  pregnancy  test does  occur  
in a study  subject  or the partner  of a male  study  subject  during  study  participation,  study  
drug must  be immediately  discontinued.  
 
Any possible premature discontinuation  would  be documented  adequately  with reasons  being  
stated,  and information  would  have  to be issued  according  to local requirements  (e.g.,  IRB, 
regulatory  authorities,  etc.).  
 
 
14.0 BIOSTATISTICS  
 
The primary  objective  of this study  is to estimate  overall  response  rate (> PR) to lenalidomide  
intensification  with or without  dexamethasone  at 6 months.    A single  stage  design  that 
differentiates  between  response  rates  of 15% and 30% will be used  to assess  efficacy  of 
lenalidomide  intensification  with or without  dexamethasone.  
The probabilities  of a type I error (falsely  accepting  a non-promising  therapy)  and type II error  
(falsely  rejecting  a promising  therapy)  are set to 0.10 and 0.10,  respectively.   The null 
hypothesis  response  rate is based  on the response  rates  ranging  from 12.5%  to 16.4%  to the 
standard  of care therapy  in patients  previously  exposed  to thalidomide  who have  relapsed  or 
refractory  disease  (reference  Webber  and Dimopoulos  papers38,39). A total of 53 patients  will be 
accrued.  At the conclusion  of the study,  if a least 12 of the 53 patients  respond  by 6 months   
the treatment  will be declared  a success.   At the end of the study,  the response  rate will be 
estimated  and a confidence  interval  will be constructed.  
We expect  to accrue  53 patients  in two years  with approximately  10-15 patients  accrued  from 
MSKCC  and the remaining  patients  accrued  from the other  centers.  
The incidence  of toxicities  of grade  2 or higher  toxicities  (CTCAE  version  4.0), the incidence  of 
probable  viral fungal  and bacterial  infections,  and the incidence  of treatment -related  mortality,  i.e., 
from causes  other  than relapse  or progression,  will be recorded  for each  patient  after each  cycle  
and at the end of study  visit. Safety  data will be described  in a variety  of ways,  both graphically  
and in tabular  form.  
 
Progression  free survival  is defined  as the time from treatment  initiation  to relapse/progression,  
death,  initiation  of non-protocol  anti myeloma  therapy,  or last follow -up.  Overall  survival  is defined  
as time from treatment  initiation  until death  or last follow -up.  Progression  free and overall  survival  
will be estimated  using  the Kaplan -Meier  method.  
 
We will estimate  the response  rate (CR, VGPR,  and PR) by 6 months  from initiation  of 
lenalidomide  intensification of lenalidomide  given  as single  agent.  For this calculation,  
patients  who have  asymptomatic  progression  after 2 cycles  of lenalidomide  and receive  
dexamethasone  will be considered  failures.  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 15.0 RESEARCH  PARTICIPANT  REGISTRATION  AND  RANDOMIZATION  
PROCEDURES  
15.1 Research  Participant  Registration  
Confirm  eligibility  as defined  in the section  entitled  Criteria  for Patient/Subject  Eligibility.  
 
Obtain  informed  consent,  by following  procedures  defined  in section  entitled  Informed  
Consent  Procedures.  
 
During  the registration  process  registering  individuals  will be required  to complete  a protocol  
specific  Eligibility  Checklist.  
 
All participants  must  be registered  through  the Protocol  Participant  Registration  (PPR)   
Office  at Memorial  Sloan -Kettering  Cancer  Center.  PPR is available  Monday  through  Friday  
from 8:30am  – 5:30pm at 646-735-8000.  Registrations  must  be submitted  via the PPR 
Electronic  Registration System (http://ppr/ ). The completed  signature  page  of the written  
consent/RA  or verbal  script/RA,  a completed  Eligibility  Checklist  and other  relevant  
documents  must  be uploaded  via the PPR Electronic  Registration  System.  
 
 
15.1.1 Research Participant Registration for Collaborating Sites 
 
Central  registration  for this study  will take place  at Memorial Sloan Kettering  Cancer  Center  
(MSKCC).  
To complete  registration  and enroll  a participant  from another  institution,  the study  staff at that site 
must  contact  the designated  research  staff at MSKCC  to notify  him/her  of the participant  
registration.  The site staff then needs  to fax registration/eligibility  documents  to Clinical  Trials  
Office,  MCT  Core  Research  Staff  at (646-227-2482).  
The following  documents  must  be sent for each  enrollment  within  24 hours  of the informed  
consent  form being  signed:  
  The completed  or partially  completed  MSKCC  eligibility  checklist  
  The signed  informed  consent  and signed  HIPAA  Authorization  form (Research  
Authorization) 
  Supporting  source  documentation  for eligibility  questions  (laboratory  results,  pathology  
report,  radiology  reports,  MD notes,  physical  exam  sheets,  medical  history,  prior treatment  
records,  and EKG report).  
 
Upon  receipt,  the research  staff at Memorial  Sloan -Kettering  Cancer  Center  will conduct  an 
interim  review  of all documents.    If the eligibility  checklist  is not complete,  the patient  will be 
registered  PENDING  and the site is responsible  for sending  a completed  form within  30 days of 
the consent.  
If the eligibility  checklist  is complete,  participant  meets  all criteria,  all source  documentation  is 
received,  the participating  site IRB has granted  approval  for the protocol,  and the site is in good  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 standing  with MSKCC,  the MSKCC  research  staff will send  the completed  registration  documents  
to the MSKCC  Protocol  Participant  Registration  (PPR)  Office  to be enrolled  as stated  in section  
15.1.   The participant  will be registered.  
 
Once  eligibility  has been  established  and the participant  is registered,  the participant  will be 
assigned  an MSKCC  Clinical  Research  Database  (CRDB)  number  (protocol  participant  number).  
This number  is unique  to the participant  and must be written  on all data and correspondence  for 
the participant.   This protocol  participant  number  will be relayed  back to study  staff at the 
registering  site via e-mail and will serve  as the enrollment  confirmation.  
 
15.2 Randomization 
 
There  is no randomization  in this study  
 
 
16.1 DATA  MANAGEMENT  ISSUES  
 
All patients  will be enrolled  on protocol  at MSKCC  and other  collaborating  centers.   We expect  to 
enroll  the necessary  53 patients  onto the study  in 2 years.  
 
A Research  Study  Assistant  (RSA)  will be assigned  to the study  at MSKCC.   The responsibilities  
of the RSA include  project  compliance,  data collection,  abstraction  and entry,  data reporting,  
regulatory  monitoring,  problem  resolution  and prioritization,  and coordination of the activities  of 
the protocol  study  team.  
 
The data collected  for this study  will be entered  into electronic  Case  Report  Forms  (eCRFs)  by 
the assigned  MSKCC  RSA.   Source  documentation  will be available  to support  the computerized  
patient  record.  
 
16.1.1  Data and Source  Documentation  for Collaborating  Sites 
Data  
Electronic  Case  Report  Forms  (eCRFs),  directions  for use and sign off requirements  have  been  
generated  for this study.  The MSKCC  Principal  Investigator  or designee  will provide  eCRFs  to 
participating  sites.   The participating  Site PI is responsible  for ensuring  these  forms  are completed  
accurately  and in a timely  manner.  
 
Source  Documentation  
 
Source  documentation refers  to original  records  of observations,  clinical  findings  and evaluations  
that are subsequently  recorded  as data.  Source  documentation  should  be consistent  with data 
entered  into eCRFs.  Relevant  source  documentation  to be submitted  throughout  the study  
includes:  
  Baseline  measures  to assess  pre–protocol  disease  status  (ex. Skeletal  
survey,  bone  marrow)  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 
  Treatment  records  
  Grade  2-5 toxicities/adverse  events  not previously  submitted  with SAE Reports  
  Response  designation  
Source  documentation  should  include  a minimum  of two identifiers  to allow  for data verification.  
MSK will maintain  the confidentiality  of any subject -identifable  information  it may encounter.  
 
16.1.2  Data  and Source  Docume  ntation  Submission  for Participating  Sites  
 
The site is responsible  for data entry  using  the Electronic  Data Capture  (EDC)  system.  Instructions  
for EDC access  and guidelines  are provided  in the study  procedure  manual.  
 
 
16.1.3  Data and Source  Documentation  Submission  Time  lines  for Participating  Sites  
 
Data  and source  documentation  to support  data should  be transmitted  via the EDC system  to 
MSKCC  according  to the following  chart:  
 
 Baseline  During  Treatment  
Cycles  SAE End of Therapy  
SUBMISSION  SCHEDULE  
 
Source  Documentation  Within  24 
hours  
(see section  
15.1.1)    
Within  24 hours  (see 
section  17.2.1  and 17.3);  
updates  to be submitted  
as available   
CRFs  Within  7 days 
of visit within  14 days of the 
end of cycle  Within  14 days of 
visit 
REQUIRED  FOLDERS/FORMS  
Screening  Folder  X    
Baseline  Folder  X    
Adverse  Event Form  X X X X 
Concomitant  Medications  
Form  X X  X 
Correlative Form  (if 
applicable)  X X  X 
Cycle  (#) Folder   X   
Off Study  Folder     X 
Serious Adverse  Event Form    X  
 
16.1.4  Data  Review  and Queries for Participating  Site Data  
Research  staff at MSKCC  will review  data and source  documentation  as it is submitted.  Data will 
be monitored  against  source documentation  and discrepancies  will be sent as queries  to the 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 participating  sites,  which the sites will resolve  electronically  in the EDC system.  MSKCC  will 
perform  oversight  of the data management  of this trial. 
 
Participating  sites should  respond  to data queries  within  14 days of receipt.  
 
 
16.1 Quality  Assurance  
 
Weekly  registration  reports  will be generated  to monitor  patient  accruals  and completeness  of 
registration  data.   Routine  data quality  reports  will be generated  to assess  missing  data and 
inconsistencies.   Accrual  rates  and extent  and accuracy  of evaluations  and follow -up will be 
monitored  periodically  throughout  the study  period  and potential  problems  will be brought  to the 
attention  of the study  team for discussion  and action  
 
Random -sample  data quality  and protocol  compliance  audits  will be conducted  by the study  team,  
at a minimum  of two times  per year,  more  frequently  if indicated.  
 
16.1.1  Investigator  responsibilities:  
 
Monthly  telephone  conference  calls will be conducted  among  the collaborating  center staff.  
Investigator  responsibilities  are set out in the ICH guideline  for Good  Clinical  Practice  (GCP)  and 
in the US Code  of Federal  Regulations.  
 
Investigators  must enter  study  data onto CRFs  or other  data collection  system.   The 
Investigator  will permit  study -related  audits  by Celgene  or its representatives,  IRB/EC  review,  
and regulatory  inspection(s)  (e.g.,  FDA,  EMEA,  TPP),  providing  direct  access  to the facilities  
where  the study  took place,  to source  documents,  to CRFs,  and to all other  study  documents.  
 
The Investigator,  or a designated  member  of the Investigator’s  staff,  must be available  at some  
time during  audits  to review  data and resolve  any queries  and to allow  direct  access  to the 
subject’s  records  (e.g.,  medical  records,  office charts,  hospital  charts,  and study  related  charts)  
for source  data verification.   The data collection  must  be completed  prior to each  visit and be 
made  available  to the Celgene  representative  so that the accuracy  and completeness  may be 
checked.  
16.1.2  Retention  of Records:  
 
All documentation  pertaining  to the conduct  of the study  and the distribution  of the study  drug,  that 
is copies  of CRFs  and source  documents  (original  documents,  data,  and records  [e.g.,  hospital  
records;  clinical  and office  charts;  laboratory  notes;  memoranda;  subject’s  diaries  or evaluation  
checklists;  SAE reports,  pharmacy  dispensing  records;  recorded  data from automated   
instruments;  copies  or transcriptions  certified after verification  as being  accurate copies;  
microfiches;  photographic  negatives,  microfilm,  or magnetic  media;  x-rays;  subject  files; and 
records  kept at the pharmacy,  at the laboratories,  and at medico -technical  departments  involved    
in the clinical  study;  documents  regarding  subject  treatment  and study  drug accountability;  original  
signed  informed  consents,  etc.]),  and all IRB correspondence  will be retained  for at least 3 years  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 after the investigation  is completed.  
 
16.1.3  Quality  Assurance  for Participating  Sites  
 
Each  site participating  in the accrual  of patients  to this protocol  will be audited  by the staff of the 
MSKCC  study  team  for protocol  and regulatory  compliance,  data verification  and source  
documentation.  Audits  may be accomplished  in one of two ways:  (1) selected  patients  records  can 
be audited  on-site at participating  sites or (2) source  documents  for selected  patients  will be sent  
to MSKCC  for audit.  Audits  will usually  be determined  by patient  accrual  numbers  and rate of 
accrual,  but can also be prompted  by reported  SAEs  or request  of Lead  PI. 
 
Audits  will be conducted  at least once  shortly  after initiation  of patient  recruitment  at a site, and if 
possible,  at the end or closeout  of the trial at a site and during  the trial if the trial lasts 3 or more  
years.  At a minimum,  audits  will be conducted  once  a year but more  frequently,  if indicated.  
The audit  will include  a review  of source  documentation  to evaluate  compliance  for: 
 
  Informed  consent  documents  and procedures  
  Adherence  to eligibility  criteria  
  Protocol  defined  treatment  
  Required  baseline,  on study  and follow -up protocol  testing  
  IRB documents  (submitted  amendments,  annual  continuing  review  reports,  SAEs)  
  Required  specimen  submission  
  Pharmacy  review,  if applicable  
  Case  Report  Form  submissions  to MSKCC:  timing  and accuracy  
 
A wrap -up session  will be conducted  at the outside  site and preliminary  findings  will be discussed  
with the outside  site PI and research  team.  The preliminary  results  will be sent to the MSKCC  PI. 
Each  audit  will be summarized  and a final report  will be sent to the PI at the audited  participating  
institution  within  30 days  of the audit.  The report  will include  a summary  of findings,  patient  by 
patient  case review,  specific  recommendations  on any performance  and/or  shortcomings  and 
request  for corrective  action,  when  necessary.  When  corrective  action  is required,  the 
participating  institution  must  reply  within  45 days of receipt  of audit  report  with their corrective  
action plan.  
 
A copy  of the audit  report  and corrective  action  plan (if applicable)  submitted  by the outside  site 
must  be sent to the MSKCC  IRB, CRQA  and maintained  in the department’s  protocol  regulatory  
binder.  
 
16.1.4  Response  Review  
Since  therapeutic  efficacy  is a stated  primary  objective,  patients’  responses  at all sites are subject  
to review  by MSKCC’s Therapeutic  Response  Review  Committee (TRRC).  Radiology,  additional  
lab reports  and possibly  bone  marrow  biopsies  and/or  aspirates  will need  to be obtained  from the 
outside  sites for MSKCC  TRRC  review  and confirmation  of response  assessment.  These  
materials  must be sent to MSKCC  within  sixty days of request  to the site. 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
  
16.2 Data  and Safety  Monitoring  
The Data  and Safety  Monitoring  (DSM)  Plans  at Memorial  Sloan -Kettering  Cancer  Center  were  
approved  by the National  Cancer  Institute  in September  2001.   The plans  address  the new policies  
set forth by the NCI in the document  entitled  “Policy  of the National  Cancer  Institute  for Data and 
Safety  Monitoring  of Clinical  Trials”  which  can be found  
at:  http://www.cancer.gov/clinicaltrials/conducting/dsm -guidelines/page1 . The DSM  Plans  at 
MSKCC  were  established  and are monitored  by the Office  of Clinical  Research.   The MSKCC  Data  
and Safety  Monitoring  Plans  can be found  on the MSKCC  Intranet  at: 
http://smsk  psps9/dept/ocr/OCR%20Website%20Documents/Clinical%20Research%20Quality%20   
Assurance%20(CRQA)/MSKCC%20Data%20and%20Safety%20Monitoring%20Plan.pdf  
 
There  are several  different  mechanisms  at MSKCC  by which  clinical  trials are monitored  for 
data,  safety  and quality.   There  are institutional  processes  in place  for quality  assurance  (e.g.,  
protocol  monitoring,  compliance  and data verification  audits,  therapeutic  response,  and staff 
education  on clinical  research  QA) and departmental  procedures  for quality  control,  plus there  
are two institutional  committees  that are responsible  for monitoring  the activities  of our clinical  
trials  programs.  The committees:  Data and Safety  Monitoring  Committee  (DSMC)  for Phase  I 
and II clinical  trials,  and the Data and Safety  Monitoring  Board  (DSMB)  for Phase  III clinical  
trials,  report  to the Center’s  Research  Council  and Institutional  Review  Board.  
 
During  the protocol  development  and review  process,  each  protocol  will be assessed  for its level 
of risk and degree  of monitoring  required.  Every  type of protocol  (e.g.,  NIH sponsored,  in-house  
sponsored,  industrial  sponsored,  NCI cooperative  group,  etc.) will be addressed  and the 
monitoring  procedures  will be established  at the time of protocol  activation.  
16.3 Regulatory  Documentation  
 
Prior  to implementing  this protocol  at MSKCC,  the protocol,  informed  consent  form,  HIPAA  
authorization  and any other  information  pertaining  to participants  must  be approved  by the 
MSKCC  Institutional  Review  Board/Privacy  Board  (IRB/PB).  Prior to implementing  this protocol  at 
the participating  sites,  approval  for the MSKCC  IRB/PB  approved  protocol  must  be obtained  from 
the participating  site’s  IRB. 
The following  documents  must  be provided  to MSKCC  before  the participating  site can be initiated  
and begin  enrolling  participants:  
 
  Participating  Site IRB approval(s)  for the protocol,  appendices,  informed  consent  form and 
HIPAA  authorization  
  Participating  Site IRB approved  consent  form and HIPPA  Authorization  
  Participating  Site IRB membership  list 
  Participating  Site IRB’s  Federal  Wide  Assurance  number  and OHRP  Registration  number  
  Curriculum  vitae and medical  license  for each  investigator and consenting  professional  
  Documentation  of Human  Subject  Research  Certification  training  for investigators  and key 
staff members  at the Participating  Site 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 
  Documentation  of Good  Clinical  Practice  (GCP)  training  for the PI and co-PI at each  
participating  site 
  Participating  site laboratory  certifications  and normals  
 
Upon  receipt  of the required  documents,  MSKCC  will formally  contact  the site and grant  
permission  to proceed  with enrollment.  
 
16.3.1  Ame ndments 
Protocol amendments 
Any amendment  to this protocol  must be agreed  to by the Principal  Investigator  and reviewed  by 
Celgene  Corporation.   Protocol  amendments  should  only be submitted  to MSKCC  IRB after 
consideration  of Celgene  review.   Written  verification  of MSKCC  IRB approval  will be obtained  
before  any amendment  is implemented.  
 
Each  change  to the protocol  document  must  be organized  and documented  by MSKCC  and first 
approved  by the MSKCC  IRB/PB.  Upon  receipt  of MSKCC  IRB/PB  approval,  MSKCC  will 
immediately  distribute  all non expedited  amendments  to the participating  sites,  for submission  to 
their local IRBs.  
Participating  sites must  obtain  approval  for all non expedited  amendments  from their IRB within  
90 calendar  days of MSKCC  IRB/PB  approval.  If the amendment  is the result  of a safety  issue,  or 
makes  eligibility  criteria  more  restrictive,  sites will not be permitted  to continuing  enrolling  new 
participants  until the participating  site IRB approval  has been  granted.  
 
The following  documents  must  be provided  to MSKCC  for each  amendment  within  the stated  
timelines:  
  Participating  Site IRB approval  
  Participating  Site IRB approved  informed  consent  form and HIPAA   authorization  
 
 
16.3.2  Additional  IRB Correspondence  
Continuing Review Approval 
The Continuing  Review  Approval  letter  from the participating  site’s  IRB and the most current  
approved  version  of the informed  consent  form should  be submitted  to MSKCC  within  7 days of 
expiration.  Failure  to submit  the re-approval  in the stated  timeline  will result  in suspension  of study  
activities.  
 
Deviations  and Violations  
 
A protocol  deviation  on this study  is defined  as a request  to treat a research  participant  who does  
not meet  all the eligibility  criteria,  pretreatment  evaluation,  or who requires  alteration  in their study  
plan.  If a deviation  from this protocol  is proposed  for a potential  or existing  participant  at MSKCC  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 or a participating  site, approval  from the MSKCC  IRB/PB  is required  prior to the action.  
Participating  sites should  contact  the MSKCC  PI who will in turn seek approval  from the MSKCC  
IRB/PB.  
A protocol  violation  is anything  that occurs  with a participant,  which  deviated  from the protocol  
without  prior approval  from the MSKCC  IRB/PB.  For protocol  violations  that are identified  after 
they occur,  the participating  site should  report  to MSKCC  as soon  as possible.  The MSKCC  PI will 
in turn report  the violation  to the MSKCC  IRB/PB.  
 
Participating  sites should  report  deviations  and violations  to their institution’s  IRBs as soon  as 
possible  per that site’s  institutional  guidelines.  Approvals/acknowledgments  from the participating  
site IRB for protocol  deviations  and violations  should  be submitted  to MSKCC  as received.  
Other  correspondence  
 
Participating  sites should  submit  other  correspondence  to their institution’s  IRB according  to local 
guidelines,  and submit  copies  of that correspondence  to MSKCC.  
 
16.3.3  Document  maintenance  
 
The MSKCC  PI and the Participating  Site PI will maintain  adequate  and accurate  records  to 
enable  the implementation  of the protocol  to be fully documented  and the data to be subsequently  
verified.  
The participating  sites will ensure  that all participating  site IRB correspondence  (IRB approval  
letters  referencing  protocol  version  date and amendment  number,  IRB approved  protocol,  
appendices,  informed  consent  forms,  deviations,  violations,  and approval  of continuing  reviews)  is 
maintained  in the regulatory  binder  on site and sent to MSKCC.  
 
A regulatory  binder  for each  site will also be maintained  at MSKCC;  this binder  may be paper  or 
electronic.  After study  closure,  the participating  site will maintain  all source  documents,  study  
related  documents  and CRFs  for 3 years.  
16.4 Noncompliance  
 
If a participating  site is noncompliant  with the protocol  document,  accrual  privileges  may be 
suspended  and/or  contract  payments  may be withheld  (if applicable),  until the outstanding  
issues  have  been  resolved.  
 
 
17.0  PROTECTION  OF HUMAN  SUBJECTS  
 
Participation  in this trial is voluntary.  All patients  will be required  to sign a statement  of 
informed  consent,  which  must conform  to MSKCC  and collaborating  centers  IRB guidelines.  
 
Patients  will be eligible  for this trial regardless  of gender  or racial/ethnic  background.   All 
patients  must  follow  the guidelines  for pregnancy  testing  birth control  and counseling related  
to the risk of fetal exposure  to lenalidomide  as outlined  in Appendix  B. 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
  
The protocol  for this study  has been  designed  in accordance  with the general  ethical  
principles  outlined  in the Declaration  of Helsinki.   The review  of this protocol  by the IRB and 
the performance  of all aspects  of the study,  including  the methods  used  for obtaining  
informed  consent,  must  also be in accordance  with principles  enunciated  in the declaration,  
as well as ICH Guidelines,  Title 21 of the Code  of Federal  Regulations  (CFR),  Part 50 
Protection  of Human  Subjects  and Part 56 Institutional  Review  Boards.  
Potential  risks and benefits  
The potential  risks of this therapy  may outweigh  the potential  benefit  in an individual  patient.  
The potential  risks to patients  are related  to drug induced  adverse  effects  and are outlined  in 
Section  11.0.  Appropriate  exclusion  criteria  for patients  are listed  in Section  6.0: Patient  
Eligibility.  Appropriate exclusion  of patients  with significant  organ  dysfunction  or infection  will 
help avoid  treatment -related toxicity.  Careful  monitoring  of laboratory  parameters  and patient  
symptoms,  along  with serial  assessment  for disease  recurrence,  will be carried  out routinely  in 
order  to minimize  the risk of adverse  effects  during  this study.  
 
Alternatives/Options for treatment 
Patients  with newly  diagnosed standard -risk multiple myeloma  have  many  treatment  options.  
Alternative  therapy  for patients  who choose  not to enroll  on this study  include  standard  
chemotherapy,  autologous  or allogeneic  stem  cell transplant,  thalidomide, steroids,  bortezomib,  
lenalidomide,  some  combination of the above,  other  clinical  trials,  observation,  or supportive  
care.  
 
Costs  
Patients  will be responsible  for all costs  related  to treatment  and complications  of treatment,  
including  all hospitalizations.   Patients  will not be responsible  for the cost of lenalidomide,  
research  blood  tests and research  bone  marrow  samples.  
 
 
17.1 Privacy  
 
MSKCC’s  Privacy  Office  may allow  the use and disclosure  of protected  health  information  
pursuant  to a completed and signed  Research  Authorization  form.   The use and disclosure  
of protected  health  information  will be limited  to the individuals  described  in the Research  
Authorization  form.   A Research  Authorization  form must  be completed  by the Principal  
Investigator and approved  by the IRB and Privacy  Board.  
Celgene  affirms  the subject’s  right to protection  against  invasion  of privacy.   In compliance  
with United  States  federal  regulations,  Celgene requires  the Investigator  to permit  their 
representatives  and, when  necessary,  representatives  of the FDA or other  regulatory  
authorities  to review  and/or  copy any medical  records  relevant  to the study  in accordance  
with local laws 
17.2 Serious Adverse Event (SAE) Reporting 
 
An adverse  event  is a new or unexpected  event  or a worsening  of an existing  condition  in a 
subject  that occurs  during  treatment  and within  the study  period,  whether  or not considered  to 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 be treatment -related.  
 
A serious  adverse  event  is one that at any dose  (including  overdose):  
 
  Results  in death  
 Is life-threatening : Life-threatening”  means  that the subject  was at immediate  risk of 
death  at the time of the serious  adverse  event;  it does  not refer to a serious  adverse  
event  that hypothetically  might  have  caused  death  if it were  more severe.  
  Requires  inpatient  hospitalization  or prolongation  of existing  hospitalization  
  Results  in persistent  or significant  disability  or incapacity :Persistent  or significant  
disability  or incapacity”  means  that there  is a substantial  disruption  of a person’s  ability  
to carry  out normal  life functions.  
  Is a congenital  anomaly  or birth defect  
  Is an important  medical  event . Medical  and scientific  judgment  should  be exercised  in 
deciding  whether  expedited  reporting  is appropriate  in situations  where  none  of the 
outcomes  listed  above  occurred.   Important  medical  events  that may not be immediately  
life-threatening  or result  in death  or hospitalization  but may jeopardize  the patient  or may 
require  intervention  to prevent  one of the other outcomes  listed  in the definition  above  
should  also usually  be considered  serious.   Examples  of such events  include  allergic  
bronchospasm  requiring  intensive  treatment  in an emergency  room or at home,  blood  
dyscrasias  or convulsions  that do not result  in inpatient  hospitalization,  or the development  
of drug dependency  or drug abuse.   A new diagnosis  of cancer during  the course  of a 
treatment  should  be considered  as medically  important.  
 
The following  event  must  also be reported  in an expedited  manner:  
 
 Pregnancy  (see section  17.4)  
 
 
Reporting  SAE to IRB At MSKCC:  
 
Any SAE must  be reported  to the IRB/PB  as soon  as possible  but no later than 5 calendar  days.  
The IRB/PB  requires  a Clinical  Research  Database  (CRDB)  SAE report  be submitted  
electronically  to the SAE Office  at sae@mskcc.org .  The report  should  contain  the following  
information:  
 
 
Fields  pop ulated  from the CRDB : 
  Subject’s  name  (generate  the report  with only initials  if it will be sent outside  of 
MSKCC)  
  Medical  record  number  
  Disease/histology  (if applicable)  
  Protocol  number  and title 
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 Data  needing  to be entered:  
 
  The date the adverse  event  occurred  
  The adverse  event  
  Relationship  of the adverse  event  to the treatment  (drug,  device,  or intervention)  
  If the AE was expected  
  The severity  of the AE 
  The intervention  
  Detailed  text that includes  the following  information:  
o An explanation  of how the AE was handled  
o A description  of the subject's  condition  
o Indication  if the subject  remains  on the study  
o If an amendment  will need  to be made  to the protocol  and/or  consent  form 
The PI’s signature  and the date it was signed  are required  on the completed  report.  
17.2.1   Reporting  SAE to Study  Supporter  (Celgene  Corporation)  
 
The investigator  should  first inform  the MSKCC  PI or designee  of any SAE (regardless  of 
causality)  within  24 hours  of being  aware  of the event.  The MSKCC  RSA will then inform  Celgene  
and collaborating  center  of these  SAEs.   The date of awareness  should  be noted  on the report.  
This must  be documented  on a CRDB  AE report  or Celgene  SAE Report  Template.  Either of these  
forms  must  be completed  and supplied  to Celgene  within  24 hours  of learning  of the event  by the 
MSKCC  RSA.  If applicable,  follow -up and resolution  reports  as described  below  must  be reported  
to Celgene.   The Celgene  tracking number  (RV-MM-PI-641) and the institutional  protocol  number  
should  be included  on SAE reports  (or on the fax cover  
letter)  sent to Celgene.   A copy of the fax transmission  confirmation  of the SAE report  to 
Celgene  should  be attached  to the SAE and retained  with the patient  records.  
 
In addition  to completing  appropriate patient  demographic  and suspect  medication  information,  
the report  should  include  the following  information:  
  Treatment  regimen (dosing  frequency,  combination  therapy)  
  Protocol  description  (and number,  if assigned)  
  Description  of event,  severity,  treatment,  and outcome  if known  
  Supportive  laboratory  results  and diagnostics  
  Investigator’s  assessment  of the relationship  of the adverse  event  to each  investigational  
product  and suspect  medication  
The investigator  will determine  which  events  are associated  with the use of the study  drugs.  
 
For reporting  purposes,  an AE should  be regarded  as possibly  related  to the use of the 
investigational  product  if the investigator  believes:  
  There  is a clinically  plausible  time sequence  between  onset  of the AE and study  drug 
administration;  and/or  
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 
  There  is a biologically  plausible  mechanism for  the study  drug causing  or contributing  to 
the AE; and 
  The AE cannot  be attributed  solely  to concurrent/underlying  illness,  other  drugs,  or 
procedures.  
 
The initial  report  must  be as complete  as possible,  including  details  of the current  illness  and 
(serious)  adverse  event,  and an assessment  of the causal  relationship  between  the event  and the 
investigational  product(s).   Information  not available  at the time of the initial  report  (e.g.,  an end 
date for the adverse  event  or laboratory  values  received  after the report)  must  be documented  on 
a follow -up report.   A final report  to document  resolution  of the SAE is required.  
 
Follow -up information  may be added  to a previously  submitted  report  by any of the following  
methods:  
  Adding  to the original  report  and submitting  it as follow -up 
  Adding  supplemental  summary  information  and submitting  it as follow -up with the 
original  form 
  Summarizing  new information  and faxing  it with a cover  letter  including  subject  identifiers  
(i.e. D.O.B.  initial,  subject  number),  protocol  description  and number,  if assigned,  
suspect  drug,  brief adverse  event  description,  and notation  that additional  or follow -up 
information  is being  submitted   (The patient  identifiers  are important  so that the new 
information  is added  to the correct  initial  report)  
 
17.3 Serious  Adverse  Event  (SAE)  Reporting  for Participating  Sites  
 
Responsibility  of Participating  Sites  
  Participating  sites are responsible  for reporting  all SAEs  to their local IRB per local 
guidelines.  Local  IRB SAE approvals/acknowledgements  must  be sent to MSK upon  
receipt.  
  Participating  sites are responsible  for reporting  all SAEs  to the MSKCC  PI via fax or 
e-mail within   24 hours  of learning  of the event.  
  Participating  sites should  notify  the MSKCC  PI of any grade  5 event  immediately.  
  Participating  sites should  use the SAE Report  Template  to report  SAEs  to MSK.  
SAE contact  information  for the Coordinating  Center  is listed  below:  
FAX:  (646)  227-2482  to the attention  of the MSKCC  MCT Core/Clinical  Trials  Office  Research  
Staff 
 
EMAIL:  Hani Hassoun,  MD (hassounh@mskcc.org)  
 
Responsibility  of MSKCC  
 
  The MSKCC  Research  Staff is responsible  for submitting  all SAEs  to the MSKCC  IRB/PB  
as specified  in 17.2 and to the Celgene  Corporation  as described  in 17.2.1.  
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 
  The MSKCC  PI is responsible  for informing  all participating  sites about  all unexpected  
SAEs  that are either  possibly,  probably  or definitely  related  to the study  intervention  
within  30 days  of receiving  the stamped  SAE from the MSKCC  IRB/PB.  
  Any report  pertaining  to a grade  5 event  will be distributed  to the participating  sites as soon  
as possible.  
17.4 Safety  Reports  
 
  MSKCC  will distribute  outside  safety  reports  to the participating  sites immediately  upon  
receipt.  
  MSKCC  must  submit  safety  reports  to the MSKCC  IRB/PB  according  to 
institutional  guidelines.  
  Participating  sites must submit  safety  reports  to their institution’s  IRBs within  30 
days  of receipt  from MSKCC  or per the local IRB institutional  guidelines.  
 
Adverse  Drug  Reaction  Reporting  
 
Toxicity  will be scored  using  CTCAE  Version  4.0 for toxicity  and adverse  event  reporting.   A 
copy  of the CTCAE  Version  4.0 can be downloaded  from the CTEP  homepage  
(http://ctep.info.n  ih.gov ).  All appropriate  treatment  areas  should have  access  to a copy of the 
CTCAE  Version  4.0.  All adverse  clinical  experiences,  whether  observed  by the investigator  or 
reported  by the patient,  must  be recorded,  with details  about  the duration  and intensity  of each  
episode,  the action  taken  with respect  to the test drug,  and the patient’s  outcome.   The 
investigator  must  evaluate  each  adverse  experience  for its relationship  to the test drug and for 
its seriousness.  
 
The investigator  must  appraise  all abnormal  laboratory  results  for their clinical  significance.   If 
any abnormal  laboratory  result  is considered clinically  significant,  the investigator  must  provide  
details  about  the action  taken  with respect  to the test drug and about  the patient’s  outcome.  
 
Pre gnancy  Reporting  
 
Pregnancies  and suspected pregnancies  (including  a positive  pregnancy  test regardless  of age or 
disease  state)  of a female  subject  occurring  while  the subject  is on lenalidomide,  or within   28 days 
of the subject’s  last dose  of lenalidomide,  are considered  immediately  reportable  events.  
Lenalidomide   is to be discontinued  immediately.  The pregnancy,  suspected pregnancy,  or 
positive  pregnancy  test must  be reported  to Celgene  Drug  Safety  immediately  by facsimile  or email  
using  the Pregnancy  Initial  Report  Form.  The female  subject  should  be referred  to an obstetrician -
gynecologist,  preferably  one experienced in reproductive toxicity  for further  evaluation  and 
counseling.  
 
The Investigator will follow  the female  subject  until completion  of the pregnancy,  and must  notify  
Celgene  Drug  Safety  immediately  about  the outcome  of the pregnancy  (either  normal  or abnormal  
outcome)  using  the Pregnancy  Follow -up Report  Form.   If the outcome  of the pregnancy  was 
abnormal  (e.g.,  spontaneous  or therapeutic  abortion),  the Investigator  should  report  the abnormal  
outcome  as an AE. If the abnormal  outcome  meets  any of the serious  criteria,  it must  be reported  
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 as an SAE to Celgene  Drug  Safety  immediately  by facsimile,  or other appropriate  method,  within  
24 hours  of the Investigator’s  knowledge  of the event  using  the SAE Report  Form.  
 
All neonatal  deaths  that occur  within  28 days of birth should  be reported,  without  regard  to 
causality,  as SAEs.  In addition,  any infant  death  after 28 days  that the Investigator  suspects  is 
related  to the in utero  exposure  to the IP should  also be reported  to Celgene  Drug  Safety  
immediately  by facsimile,  or other appropriate  method,  within  24 hours  of the Investigator’s  
knowledge  of the event  using  the SAE Report  Form.  
 
Male  Subjects  
 
If a female  partner  of a male  subject  taking  investigational  product  becomes  pregnant,  the male  
subject  taking  lenalidomide   should  notify  the Investigator,  and the pregnant  female  partner  should  
be advised  to call their healthcare  provider  immediately.  
Celgene Drug Safety Contact Information: 
 
Ce lgene  Corporation  
Global  Drug  Safety  and Risk Manage  ment  
Connell  Corporate  Pa rk 
300 Connell  Dr. Suite  6000  
Berke  ley He ights,  NJ  07922  
Fax: ( 908)  673-9115   
E-mail:   drugsafety@celgene.com   
 
 
Adverse  event  updates/IND  safety  reports  
 
Celgene  shall notify  the Investigator  via an IND Safety  Report  of the following  information:  
 
  Any AE associated  with the use of study  drug in this study  or in other  studies  that is both 
serious  and unexpected.  
  Any finding  from tests in laboratory  animals  that suggests  a significant  risk for human  
subjects  including  reports  of mutagenicity,  teratogenicity,  or carcinogenicity.  
 
The Investigator  shall notify  his/her  IRB promptly  of these  new serious  and unexpected  AE(s) or 
significant  risks to subjects.  
 
The Investigator  must  keep copies  of all AE information,  including  correspondence  with Celgene  
and the IRB, on file. 
Annual  Reports  to Celgene  
 
This study  meets  requirements  for IND exemption.  Annual  report  must  be submitted  to Celgene  
for review/approval:  
 
Celgene  Corporation  
Attn: Medical  Development  
Amended:   04/14/15  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)   
 86 Morris  Avenue  
Summit,  NJ  07901  
Tel: (908)  673-9000  
 
All adverse  experience  reports  must  include  the patient  number,  age, sex, weight,  severity  of 
reaction  (mild,  moderate,  severe),  relationship  to study  drug (probably  related,  unknown  
relationship,  definitely  not related),  date and time of administration  of test medications  and all 
concomitant  medications,  and medical  treatment  provided.    The investigator  is responsible  for 
evaluating  all adverse  events  to determine  whether  criteria  for “serious”  and as defined  above  
are present.   The investigator  is responsible  for reporting  adverse  events  to Celgene  as 
described  below.  
 
 
18.1 INFORMED  CONSENT  PROCEDURES  
Before  protocol -specified  procedures  are carried  out, consenting  professionals  will explain  full 
details  of the protocol  and study  procedures  as well as the risks involved  to participants  prior to  
their inclusion  in the study.  Participants  will also be informed  that they are free to withdraw  from the 
study  at any time.  All participants  must  sign an IRB/PB -approved  consent  form indicating  their 
consent  to participate.  This consent  form meets  the requirements  of the Code  of Federal  
Regulations  and the Institutional  Review  Board/Privacy  Board  of this Center.  The consent  form will 
include  the following:  
 
1. The nature  and objectives,  potential  risks and benefits  of the intended  study.  
2. The length of study  and the likely  follow -up required.  
3. Alternatives  to the proposed  study.  (This  will include  available  standard  and investigational  
therapies.  In addition,  patients  will be offered  an option  of supportive  care for therapeutic  
studies.)  
4. The name  of the investigator(s)  responsible  for the protocol.  
5. The right of the participant  to accept  or refuse  study  interventions/interactions  and to 
withdraw  from participation  at any time.  
 
Before  any protocol -specific  procedures  can be carried  out, the consenting  professional  will fully 
explain  the aspects  of patient  privacy  concerning  research  specific  information.   In addition  to 
signing  the IRB Informed  Consent,  all patients  must agree  to the Research  Authorization  
component  of the informed  consent  form.  
 
Each  participant  and consenting  professional  will sign the consent  form.  The participant  must  
receive  a copy  of the signed  informed  consent  form.  
 
18.1 FOR  PARTICIPATING SITES  
 
The investigators  listed  on the protocol  cover  page  and their qualified  designees  at each 
participating  site may obtain  informed  consent  and care for the participants  according  to good  
clinical  practice  and protocol  guidelines.  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 Signed  copies  of the informed  consent  should  be distributed  as follows:  One copy will be given  to 
the participant  to be retained  for their personal  records.  One copy will be maintained  on file at the 
MSKCC.  The third copy will be confidentially  maintained  by the participating  institution.  
A note will be placed  in the medical  record  documenting  that informed  consent  was obtained  for 
this study,  and that the participant  acknowledges  the risk of participation.  
 
 
19.1 REFERENCES  
 
1. Smith  A, Wisloff  F, Samson  D: Guidelines  on the diagnosis  and management  of 
multiple  myeloma  2005.  Br J Haematol  132:410 -51, 2006  
2. Jemal  A, Murray  T, Ward  E, et al: Cancer  statistics,  2005.  CA Cancer  J Clin 
55:10 -30, 2005 
3. Laubach  J, Richardson  P, Anderson  K: Multiple  myeloma.  Annu  Rev Med 
62:249 -64, 2011  
4. Anderson  KC, Alsina  M, Bensinger  W, et al: NCCN  clinical  practice  guidelines  in 
oncology:  multiple  myeloma.  J Natl Compr  Canc  Netw  7:908 -42, 2009  
5. Barlogie  B, Shaughnessy  J, Tricot  G, et al: Treatment  of multiple  myeloma.  Blood  
103:20 -32, 2004  
6. Fermand  JP, Katsahian  S, Divine  M, et al: High-dose  therapy  and autologous  
blood  stem -cell transplantation  compared  with conventional  treatment  in myeloma  patients  aged  
55 to 65 years:  long-term results  of a randomized  control  trial from the Group  Myelome - 
Autogreffe.  J Clin Oncol  23:9227 -33, 2005  
7. Jagannath  S, Durie  BG, Wolf J, et al: Bortezomib  therapy  alone  and in 
combination  with dexamethasone  for previously  untreated  symptomatic  multiple  myeloma.  Br J 
Haematol  129:776 -83, 2005  
8. Richardson  P, Chanan -Khan,  A, Schlossman,  R, Munshi,  N, Oaklander,A.L.,  
Heffner,  L., Hassoun,  H. Avigan,  D. Amato,A.  Anderson,  K: Multicenter  Phase  2 Study  of 
Bortezomib  in Previously  Untreated  Multiple  Myeloma  (MM);  Encouraging  Single -agent  Activity  
and Tolerability  Despite  High Rates  of Baseline  Peripheral  Neuropathy.  Blood 106, 2005  
9. Dispenzieri  A, Blood,  E., Vesole,  D., Fonseca,  R., Callender,  N., Pr, G.,  : A  
phase  II study  of PS-341 for patients  with high risk, newly  diagnosed  multiple  myeloma:  A trial of 
the ECOG  group  (E2A02).  Blood 106, 2005  
10. Harousseau  JL, Attal M, Leleu  X, et al: Bortezomib  plus dexamethasone  as 
induction  treatment  prior to autologous  stem  cell transplantation  in patients  with newly  
diagnosed  multiple  myeloma:  results  of an IFM phase  II study.  Haematologica 91:1498 -505, 
2006  
11. Wang  M, Giralt  S, Delasalle  K, et al: Bortezomib  in combination  with thalidomide - 
dexamethasone  for previously  untreated  multiple  myeloma.  Hematology  12:235 -9, 2007  
12. Wang  M, Weber  DM, Delasalle  K, et al: Thalidomide -dexamethasone  as primary  
therapy for advanced multiple myeloma. Am J Hematol 79:194-7, 2005 
13. Mateos  MV, Hernandez  JM, Hernandez  MT, et al: Bortezomib  plus melphalan  
and prednisone  in elderly  untreated  patients  with multiple  myeloma:  results  of a multicenter  
phase  1/2 study.  Blood  108:2165 -72, 2006  
14. Mateos  MV, Hernandez  JM, Hernandez  MT, et al: Bortezomib  plus melphalan  
and prednisone in elderly  untreated  patients  with multiple  myeloma:  updated time -to-events  
results  and prognostic  factors  for time to progression.  Haematologica  93:560 -5, 2008  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 15. Oakervee  HE, Popat  R, Curry  N, et al: PAD combination  therapy  (PS- 
341/bortezomib,  doxorubicin  and dexamethasone)  for previously  untreated  patients  with multiple  
myeloma.  Br J Haematol  129:755 -62, 2005  
16. Popat  R, Oakervee  HE, Hallam  S, et al: Bortezomib,  doxorubicin  and 
dexamethasone  (PAD)  front-line treatment  of multiple  myeloma:  updated  results  after long-term 
follow -up. Br J Haematol  141:512 -6, 2008  
17. Attal M, Harousseau  JL, Stoppa  AM, et al: A prospective,  randomized  trial of 
autologous  bone marrow  transplantation and chemotherapy  in multiple myeloma.  Intergroupe  
Francais  du Myelome.  N Engl J Med 335:91 -7., 1996  
18. Child  JA, Morgan  GJ, Davies  FE, et al: High-dose  chemotherapy  with 
hematopoietic  stem -cell rescue  for multiple  myeloma.  N Engl J Med 348:1875 -83, 2003  
19. Lenhoff  S, Hjorth  M, Holmberg  E, et al: Impact  on survival  of high-dose  therapy  
with autologous  stem cell support  in patients  younger  than 60 years  with newly  diagnosed  
multiple  myeloma:  a population -based  study.  Nordic  Myeloma  Study  Group.  Blood  95:7-11., 
2000  
20. Palumbo  A, Triolo  S, Argentino  C, et al: Dose -intensive  melphalan  with stem cell 
support  (MEL100)  is superior  to standard  treatment in elderly  myeloma  patients.  Blood 94:1248 - 
53., 1999  
21. Koreth  J, Cutler  CS, Djulbegovic  B, et al: High-dose  therapy  with single  
autologous  transplantation  versus  chemotherapy  for newly  diagnosed  multiple  myeloma:  A 
systematic  review  and meta -analysis  of randomized  controlled  trials.  Biol Blood  Marrow  
Transplant  13:183 -96, 2007  
22. Ladetto  M, Pagliano  G, Ferrero  S, et al: Major  tumor  shrinking  and persistent  
molecular  remissions  after consolidation  with bortezomib,  thalidomide, and dexamethasone  in 
patients  with autografted  myeloma.  J Clin Oncol  28:2077 -84, 2010  
23. Ludwig  H, Adam  Z, Tothova  E, et al: Thalidomide  maintenance  treatment  
increases  progression -free but not overall  survival  in elderly  patients  with myeloma.  
Haematologica  95:1548 -54, 2010  
24. Brinker  BT, Waller  EK, Leong  T, et al: Maintenance  therapy  with thalidomide  
improves  overall  survival  after autologous  hematopoietic  progenitor  cell transplantation  for 
multiple  myeloma.  Cancer  106:2171 -80, 2006  
25. Cavo  M, Pantani  L, Tacchetti  P, et al: Thalidomide  maintenance  in multiple  
myeloma:  certainties  and controversies.  J Clin Oncol  27:e186 -7; author  reply  e188,  2009 
26. Berenson  JR, Crowley  JJ, Grogan  TM, et al: Maintenance  therapy  with alternate - 
day prednisone  improves  survival  in multiple  myeloma  patients.  Blood 99:3163 -8, 2002  
27. Attal M, Harousseau  JL, Leyvraz  S, et al: Maintenance  therapy  with thalidomide  
improves  survival  in patients  with multiple  myeloma.  Blood  108:3289 -94, 2006  
28. Zonder  JA, Crowley  J, Hussein  MA, et al: Lenalidomide  and high-dose 
dexamethasone  compared  with dexamethasone as initial  therapy  for multiple  myeloma:  a 
randomized  Southwest  Oncology  Group  trial (S0232).  Blood  116:5838 -41, 2010  
29. Rajkumar  SV, Jacobus  S, Callander  NS, et al: Lenalidomide  plus high-dose  
dexamethasone  versus  lenalidomide  plus low-dose  dexamethasone as initial  therapy  for newly  
diagnosed  multiple  myeloma:  an open -label randomised  controlled  trial. Lancet  Oncol  11:29 -37, 
2010  
30. McCarthy  PL, Owzar  K, Stadtmauer  EA, et al: Phase  III Intergroup  Study  of 
Lenalidomide  (CC-5013)  Versus  Placebo  Maintenance  Therapy  Following  Single  Autologous  
Stem  Cell Transplant  for Multiple  Myeloma  (CALGB  100104):  Initial  Report  of Patient  Accrual  
and Adverse  Events.  ASH Annual  Meeting  Abstracts  114:3416 -, 2009  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 31. Attal M, Harousseau  JL, Marit  G, et al: Lenalidomide  After Autologous  
Transplantation  for Myeloma:  First Analysis  of a Prospective,  Randomized  Study  of the 
Intergroupe  Francophone  Du Myelome  (IFM 2005  02). ASH Annual  Meeting  Abstracts  114:529 -, 
2009  
32. Richardson  PG, Weller  E, Jagannath  S, et al: Multicenter,  phase  I, dose - 
escalation  trial of lenalidomide  plus bortezomib  for relapsed  and relapsed/refractory  multiple  
myeloma.  J Clin Oncol  27:5713 -9, 2009  
33. Richardson  P, Jagannath  S, Schlossman  RL, et al: Multicenter,  randomized,  
phase  II study  to evaluate  the efficacy  and safety  of two CC-5013  dose  regimens  when  used  
alone  or in combination  with dexamethasone  for the treatment  of relapsed  or refractory  multiple  
myeloma  (MM).  Blood  100:104a,  2002  
34. Alegre A, Granda A, Martinez-Chamorro C, et al: Different patterns of relapse 
after autologous  peripheral  blood  stem  cell transplantation  in multiple  myeloma:  clinical  results  
of 280 cases  from the Spanish  Registry.  Haematologica  87:609 -14, 2002  
35. Lenhoff  S, Hjorth  M, Turesson  I, et al: Intensive  therapy  for multiple  myeloma  in 
patients  younger  than 60 years.  Long -term results  focusing  on the effect  of the degree  of 
response  on survival  and relapse  pattern  after transplantation.  Haematologica  91:1228 -33, 2006  
36. Kumar  S, Mahmood  ST, Lacy  MQ, et al: Impact  of early  relapse  after auto-SCT 
for multiple  myeloma.  Bone  Marrow  Transplant  42:413 -20, 2008  
37. Kumar  SK, Rajkumar  SV, Dispenzieri  A, et al: Improved  survival  in multiple  
myeloma  and the impact  of novel  therapies.  Blood 111:2516 -20, 2008  
38. Webber,DM,  Chen,  C, Niesvizky,R,  et al: Lenalidomide  plus 
dexamethasone  for relapsed  multiple  myeloma  in North  America.  New Engl Jour.  Med 
357:2133,  2007  
39. Dimopoulos  M, Spencer,  A, Attal M, et al: Lenalidomide  plus 
dexamethasone  for relapse  or refractory  multiple  myeloma.   New Engl Jour.  Med 
357:2123,  2007  
 
 
20.0 APPENDICES  
 
Appendix  A: Criteria  For Symptomatic  Relapse  And Progression  Of Multiple  Myeloma  
 
Appendix  B: Lenalidomide  Risks  Of Fetal  Exposure,  Pregnancy  Testing  Guidelines  And 
Acceptable  Birth Control  Methods  
 
Appendix  C: Cockcroft -Gault  Estimation  Of Crcl 
 
Appendix  D: Medication  Diary/Log  For Lenalidomide  And Dexamethasone  
 
Appendix  E: ECOG  Performance  Status  
 
 
 
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 APPENDIX  A: CRITERIA  FOR  SYMPTOMATIC  AND  
ASYMPTMATIC  RELAPSE  AND  PROGRESSION  OF MULTIPLE  
MYELOMA  
 
 
Patients  will be considered  as having  symptomatic  relapse/progression  of disease  if the y show  
evidence  of disease  relapse  or progression  by serum  or urine  studies  according  to consensus  
criteria,  AND  present  any of the following  organ  dysfunctions  that are deemed  to be related  to 
disease  progression:  
[C] Calcium  elevation  in the blood  (serum  calc ium > 10.5 mg/l or upper  limit of 
normal) 
[R] Progressive  renal  insuffic  iency (serum  creatinine  > 2mg/dl)  
[A] Progressive  anemia  with hemoglobin < 9 g/dl 
[B] New  lytic lesion  by skeletal survey  
 
 
Patients  will be considered  as having  asymptomatic  relapse/progression  if they show  evidence  of 
disease  relapse  or progression  by serum  or urine  studies  according  to consensus  criteria  without  
evidence  of organ  damage  as defined  above.  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 APPENDIX  B: LENALIDOMIDE  RISKS  OF FETAL  EXPOSURE,  
PREGNANCY  TESTING  GUIDELINES  AND  ACCEPTABLE  
BIRTH  CONTROL  METHODS  
 
Risks  Associate  d with Pre gnancy  
 
The use of lena lidomide  in pregnant  females and nursing  mothers  has not been  studied  nor has the 
effect  of the lenalidomide  on human  eggs and sperm.  Lenalidomide  is structura  lly related  to 
thalidomide.   Thalidomide  is a known  human  teratogenic  active  substance that causes  severe  life- 
threatening  birth  defects.  An embryofeta  l deve lopme  nt study  in anima  ls indicates  that lena lidomide  
produced  malformations in the offspring  of female  monkeys  who received  the drug during  
pregnancy.   The teratoge  nic effect  of lenalidomide  in huma  ns cannot  be ruled  out.  Therefore,  a risk 
minimization  plan to preve  nt pregnancy  must  be observed.  
 
All study  participants  must be registered  into the  ma ndatory  Revlimid  REMS™  program,  and be 
willing  and able to comply  with the requirements  of Revlimid  REMS™.  
 
Crite  ria fo r fe male  s of childbe  aring  pote ntial (FCB  P) 
This protocol  defines  a female  of childbearing  potential as a sexually mature  female  who:  1) has not 
undergone  a hysterectomy  or bilateral  oophorectomy  or 2) has not been  naturally  postmenopausal  
for at least 24 consecutive  months  (i.e., has had menses  at any time in the preceding  24 consecutive  
months).  
 
The investigator  mus t e ns ure that:  
• Females  of childbearing  potentia  l comply  with the conditions  for pregnancy  risk 
minimization,  inc luding  confirmation  that she has an adequate  leve l of understanding  
• Females  NOT of childbearing  pote ntia l acknowledge  that she understands  the ha zards  and 
necessary  precautions  assoc  iated  with the use of lena lidomide  
• Male  patients  taking  le nalidomide  acknowledge  that he understands  that traces  of 
lena lidomide  have been  found  in semen,  that he understands  the potentia  l teratogenic  risk if 
engaged  in sexual  activity  with a female  of childbearing  pote ntia l or pregnant  female, and 
that he understands  the need  for the use of a condom  even  if he has had a vasectomy,  if 
engaged  in sexual  activity  with a female  of childbearing  pote ntia l or pregnant  female. 
• 
Contrace  ption  
Females  of childbearing  potentia  l (FCBP)  enrolle  d in this protocol  must agree  to use two reliable 
forms  of contraception  simultaneously  or to practice  complete  abstine  nce from  heterosexua  l 
intercourse  during  the following  time periods  related  to this study:  1) for at least 28 days before  
starting  lena lidomide;  2) throughout  the entire  duration  of lena lidomide  treatment;  3) during  dose 
interruptions;  and 4) for at least 28 days after lena lidomide  discontinuation.  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 The two methods  of reliable contraception  must inc lude one highly  effective  method  and one 
additiona  l effective  (barrier)  method.  FCBP  must be referred  to a qualifie d provider  of contraceptive  
methods  if needed.  The following  are examples  of highly  effective  and additiona  l effective  methods  
of contraception:  
o Highly  effective  methods:  
▪ Intrauterine  device  (IUD)  
▪ Hormona  l (birth  control  pills,  injections,  impla  nts) 
▪ Tuba  l ligation  
▪ Partner’s  vasectomy  
o Additiona  l effective  methods:  
▪ Male  condom  
▪ Diaphragm  
▪ Cervical Cap 
Because  of the increased  risk of ve nous thromboembolism  in patients  with multiple  mye loma  taking  
lena lidomide  and dexamethasone  , combine  d ora l contraceptive  pills are not recommended.  If a 
patie nt is currently  using  combine  d ora l contraception  the patie  nt should  switch  to one of the 
effective  method  listed  above.  The risk of venous  thromboembolism  continues  for 4−6 weeks  after 
discontinuing  combine  d ora l contraception.  The efficacy  of contraceptive  steroids  may be reduced  
during  co-treatme  nt with dexamethasone. 
Implants  and levonorgestrel -re leasing  intrauterine  systems  are associated  with an increased  risk of 
infection  at the time of insertion  and irregular  vagina  l bleeding.  Prophylactic  antibiotics  should  be 
considered  particularly  in patients  with ne utropenia.  
 
Pre gnancy  tes ting 
Medically  supervised  pregnancy  tests with a minimum  sensitivity  of 50 mIU/mL  must  be performed  
for females  of childbearing  potentia  l, inc luding  females of childbearing  potentia  l who commit  to 
complete  abstinence,  as outlined  below. 
 
Before starting le nalidomide 
 
Female  Patients:  
FCBP  must have two negative  pregna  ncy tests (sensitivity  of at least 50 mIU/mL)  prior to 
prescribing  le nalidomide.   The first pregnancy  test must  be performed  within  10-14 days prior  to 
prescribing  le nalidomide  and the second  pregnanc  y test must be performed  within  24 hours  prior  to 
prescribing  le nalidomide.   The patie nt may not receive  lena lidomide  until the Investigator  has 
verified that the results  of these  pregnancy  tests are negative.  
 
Male  Patients : 
Must  agree  to practice  complete  abstinence  or agree  to use a condom  during  sexual  contact  with 
pregnant  females or females of childbearing  pote ntia l throughout  the entire  duration  of lena lidomide  
treatment,  during  dose interruptions  and for at least 28 da  ys following  le nalidomide  discontinuation,  
even  if he has undergone  a successful  vasectomy.  
 
During  study  partic  ipation  and for 28 days following  lena lidomide  disc ontinuation  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 Female  Patients:  
• FCBP  with regular  or no menstrua  l cyc les must agree  to have pregnancy  tests weekly  for the 
first 28 days of lena lidomide  treatment,  inc luding  dose interruptions  and the n every  28 days 
throughout  the remaining duration  of le nalidomide  treatment,  inc luding  dose interruptions,  at 
lena lidomide  discontinuation,  and at Day 28 following  lena lidomide  discontinuation.   If 
menstrua  l cyc les are irregular,  the pregnancy  testing  must  occur  weekly  for the first 28 days 
of le nalidomide  treatment,  inc luding  dose interruptions, and then every  14 days throughout  
the remaining  duration  of lena lidomide  treatment,  inc luding  dose interruptions,  at 
lena lidomide  discontinuation,  and at Day 14 and Day 28 following  lena lidomide  
discontinuation.  
• At each  visit, the Investigator  must  confirm  with the FCBP  that she is continuing  to use two 
reliable  methods  of birth  control  at each  visit during  the time that birth  control is required.  
• If pregnancy  or a positive  pre gnancy  test does  occur  in a study  patient,  lena lidomide  must  be 
immediately  discontinued.  
• Pregnancy  testing  and counse  ling must be performed  if a patient  misses  her period  or if her 
pregnancy  test or her menstrua  l bleeding  is abnorma  l.  Lenalidomide  treatment  must  be 
temporarily  discontinued  during  this evaluation.  
• Females  must  agree  to abstain  from  breastfeeding  during  study  participation  and for at least 
28 days after le nalidomide  discontinuation.  
Male  Patients:  
• Must  practice  complete  abstine  nce or use a condom  during  sexua  l contact with pregnant  
females  or females of childbearing  potentia  l throughout  the entire  duration  of lena lidomide  
treatment,  during  dose interruptions  and for at least 28 da  ys following  le nalidomide  
discontinuation,  even  if he has undergone  a successful  vasectomy.  
• If pregnancy  or a positive  pre gnancy  test does occur  in the partner  of a male study  patient  
during study participation, the investigator must be notifie d immediately. 
• Male  patients  should  not donate  semen  or sperm  during  therapy  or for at least 28 days 
following  discontinuation  of lena lidomide.  
• 
Additional  pre cautions  
• Patients  should  be instructed  never  to give lena lidomide  to another  person.  
• Patients  should  not donate  blood  during  therapy  and for at least 28 days following  
discontinuation  of lena lidomide.  
• Only  enough  lena lidomide  for one cycle  of therapy  may be prescribed  with each  cycle  of 
therapy.  
• Any unused  lena lidomide  must be returned  as instructed  through  Revlimid  REMS™.  
MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL  
IRB#:  11-107A(12)  
Amended:   04/14/15   
 A P P END  I X C : Cockcroft -Gault  estimation  of CrCl:  
 
 
Cockcroft -Gault  estimation  of creatinine  clearance  (CrCl):  
(Cockcroft,  1976;  Luke  1990)  
 
CrCl  (mL/min)  = (140 –age) x (weight  , kg)   
(Males ) 72 x (serum  creatinine,  mg/dL)  
 
CrCl  (mL/min)  = (140 –age) x (weight  , kg)_    x 0.85 
(Females) 72 x (serum  creatinine  , mg/dL)  
Amended:   04/14/15  MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL   
  
APPENDIX  D: Pill Diary  for IRB #11-107 
 
Number  of Pills Given:_     
 
 
Pill Bottle(s) returned: Circle Yes or No IRB#:  11-107A(12)  
Total  Daily  Dose:  _ Number  of Pills returned :_   
(To be Completed  by RN) 
 
PLEASE  FILL  OUT  AND  BRING  THIS  SHEET  AT YOUR  NEXT  VISIT.  This  lo g should  be completed  each  time you 
take the study  medication  at home,  and returned  at the end  of each  cycle.  If you miss  a dose,  please  indicate  in the table  
below.  
CYCLE  #: _   # of WEEKS_    
 
Day Date Number  of Lenalidomide  
capsules  taken  (please  indicate  
time)  Dexamethasone  tablets  taken  
(please  indicate  time)  
EXAMPLE 1/1/2011  2, 4:00 PM 1, 3:00 PM 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
25    
26    
27    
28    
Patient  Signature:     Date:  __   
Consenting  Professional/Research  RN Signature:  __________________  Date:     _   
Consenting  Professional/Research  RN 
Comments:  _ 
_   

MEMORIAL SLOAN -KETTERING  CANCER  CENTER  
IRB PROTOCOL   
 
 
APPENDIX E: ECOG Performance Status IRB#:  11-107A(12)  
 
Grade  Description  
0 Normal activity,  fully  active,  able to carry  on all pre-disease  performance  
without  restriction  
 
1 Symptoms,  but fully  ambulatory,  restricted  in physica  lly strenuous  activity  
but ambulatory  and able to carry  out work  of a light or sedentary  nature  (e.g. 
light housework,  office  work)  
2 Ambulatory  and capable  of all self-care but unable  to carry  out any work  
activities.   Up and about  more  than 50% of waking  hours.  
3 Capable  of only limited  self-care,  Confined  to bed or cha ir more  than 50% of 
waking  hours.  
4 Complete  ly disabled.   Cannot  carry  on any self-care.  Totally  confined  to bed 
or chair.  
5 Death  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amended:   04/14/15  
